

Author index

A

Abraham, A.A. 31
 Abrahamsson, H. 79
 Acampora, R. 123
 Addicks, K. 1157
 Adzuma, K. 381
 Agosti, K. 1313
 Agostini, G. 739
 Åhrén, B. 395
 Åkerblom, H.K. 97, 705, 1042
 Alberti, K.G.M.M. 699
 Alcolado, J.C. 376, 1482
 Alcolado, R. 1482
 Aldington, S.J. 437
 Alford, F. 326
 Alzaid, A. 337
 Amadio, L. 711
 Amato, L. 1295
 Amiel, S.A. 1412
 Amoretti, R. 848
 Andersen, H. 1191
 Andersson, A. 543
 Andersson, H. 79
 Andreani, D. 848
 Andrikopoulos, S. 1389
 Anello, M. 55, 779
 Anfossi, G. 936
 Annuzzi, G. 1419
 Aparicio, S.R. 1455
 Arakawa, K. 1434
 Araki, E. 422
 Araki, S. 193
 Archer, D.B. 1271
 Ariano, D. 403
 Arie, H. 792
 Arner, P. 128
 Aronica, R. 1076
 Arrieta, F.J. 1262
 Arslanoğlu, İ. 629
 Asahi, Y. 1033
 Asfari, M. 927
 Asplund, K. 1061
 Assan, R. 283
 Assmann, K.J.M. 161, 1169
 Atkinson, A.B. 853
 Attvall, S. 79
 Aunis, D. 180
 Awata, T. 748

B

Bachmann, S. 525
 Baier, L.J. 461
 Baird, J.D. 1055
 Bakker, M.A.H. 161, 1169
 Balaun, E. 122
 Baldo, L. 1076
 Ballhausen, T. 1157
 Bangstad, H.-J. 1197, 1320
 Barceló, J. 62
 Barlow, S.W. 906
 Barnes, P.R.J. 1205
 Baroni, M.G. 848
 Barrow, B.A. 693

Baum, H. 875
 Baumgartner-Parzer, S.M. 1367
 Bazzigaluppi, E. 816
 Becker, D.J. 1090
 Beck-Nielsen, H. 326
 Bedford, C. 1183
 Beech, J.S. 889
 Beks, P.J. 86
 Bell, G.I. 211, 1055, 1466, 1479
 Bell, P.M. 853
 BenDahan, D. 1485
 Bender, R. 227
 Bending, J.J. 252
 Bendtzen, K. 153
 Bennett, P.H. 187, 221, 1487
 Benthem, L. 919
 Berden, J.H.M. 124, 161, 1169
 Berger, M. 227
 Bergström, B. 1003
 Berrish, T.S. 699
 Bertrams, J. 351
 Biessels, G.J. 251
 Binder, A. 126
 Bingley, P.J. 816
 Biro, P.A. 752
 Bishop, D.T. 221, 1487
 Bjørnbæk, C. 1230
 Björck, S. 216
 Björn, S.F. 1197
 Björnsson, E. 79
 Blanché, H. 378
 Bloch, W. 1157
 Blohmé, G. 216
 Boari, L. 306
 Bocconi, M.L. 848
 Boden, G. 1307
 Boel, E. 14
 Boelskifte, S. 798
 Boemi, M. 711
 Bogardus, C. 461, 1213
 Bognetti, E. 816
 Boivin, S. 577
 Bolli, G. 106
 Bolli, G.B. 244
 Bonadonna, R.C. 518
 Bonifacio, E. 751, 816, 968
 Bonora, E. 318, 672
 Borboni, P. 445
 Borch-Johnsen, K. 798
 Born, J. van den 161, 1169
 Boroujerdi, M. 1007
 Bosi, E. 816, 968
 Bottazzo, G. 126
 Bottazzo, G.F. 816
 Bottini, P. 244, 1003
 Boucher, B.J. 1125, 1239
 Bouix, O. 494
 Boulton, A.J.M. 1051
 Bouter, L.M. 86
 Bouwens, L. 1405
 Bowsher, R. 1328
 Bozzetti, A.M. 306
 Braghi, S. 816
 Brambilla, P. 739
 Brammert, M. 1003

Brandenburg, D. 1007
 Bravenboer, B. 251
 Breimer, L. 630
 Bressan, F. 318
 Bretzel, R.G. 656
 Brismar, K. 474
 Brismar, T. 685
 Broucker, U. 1397
 Brownlee, M. 269, 656
 Brun, J.F. 494
 Brunetti, P. 244
 Brunk, U. 635
 Bruno, A. 1218
 Bucci, M.G. 804
 Bundak, R. 629
 Buongiorno, A. 518
 Burcelin, R. 283
 Burden, A.C. 467
 Buscema, M. 39, 779
 Buyschaert, M. 253
 Buzzetti, R. 126, 848
 Byrne, C.D. 1358

C

Cacciatori, V. 318
 Cagliero, E. 785
 Caiola, S. 518
 Calori, G. 306
 Caltabiano, V. 39, 779
 Calvillan, M. 378
 Cambien, F. 798
 Cameron, N.E. 1285, 1475
 Campagnola, M. 1122
 Campea, L. 848
 Canessa, M. 785
 Carrasco et al., E. 378
 Carroll, C.A. 732
 Casanova, B. 1262
 Casetta, B. 1117
 Casla, A. 1262
 Cassone Faldetta, M. 848
 Castellino, P. 732
 Casucci, G. 244
 Catinella, S. 1076
 Caumo, A. 739
 Cavallo, M.G. 848
 Cavallo-Perin, P. 1218
 Cavalot, F. 936
 Cerasi, E. 992
 Ceriello, A. 1484
 Chaiken, R.L. 1307
 Chakravarthy, U. 1271
 Chandramouli, V. 831
 Charles, M.A. 187
 Chase, H.P. 1353
 Chaturvedi, N. 630
 Cheng, I.K.P. 604
 Chiu, K.C. 1490
 Chiumello, G. 739
 Christopher, M. 326
 Chuang, L.-M. 1490
 Ciani, F. 672
 Cicconetti, C.A. 848
 Clark, A. 868

Clark, A.E. 661
 Clark, S. 1131
 Cobelli, C. 739
 Cohen, A.M. 899
 Cohen, N. 378
 Cohen, P.T.W. 461
 Cohen, R.D. 889
 Colle, E. 715
 Collins, P. 1300
 Colucci, G.B. 573
 Cominacini, L. 1122
 Concannon, P. 1479
 Cooper, M. 1493
 Cooper, M.E. 387
 Corbellini, M. 318
 Cotter, M.A. 1285, 1475
 Cox, N.J. 1479
 Cozzone, P.J. 1485
 Crémel, G. 180
 Crellin, D.M. 1455
 Crepaldi, G. 672
 Crinò, A. 848
 Cummings, M.H. 959
 Cupisti, S. 227
 Cushman, S.W. 661
 Czernichow, P. 927

D

Dahlquist, G. 874, 1371
 D'Alfonso, R. 445
 D'Amore, A. 1295
 Danilov, S. 798
 D'Autilia, M.L. 430
 Davis, E.M. 1466
 Davison, A.M. 1455
 Davoli, A. 1122
 Dawson, D. 454
 Day, N.E. 1358
 De Leiva, A. 633
 De Marco, R. 318
 De Maria, R. 953, 1449
 De Mattia, G.C. 848
 De Santis, A. 1122
 De, W. 927
 Deeb, S.S. 617
 DeFronzo, R.A. 732
 Degano, C. 779
 Dekel, N. 753
 Demaine, A. 1495
 Demaine, A.G. 623
 Demura, H. 792
 Denver, A.E. 356
 Denver, E. 454
 D'Erme, M. 1117
 Desai, N.G. 251
 Desnuelle, C. 1485
 Després, J.-P. 631
 Dewhurst, M. 129
 Dey, J. 251
 Di Marino, L. 1419
 Di Mario, U. 1117
 Diderholm, H. 1371
 Dijkman, H.B.P.M. 1169
 Dimitriadis, E. 1300

Dines

Dines, K. C. 1285
Dinneen, S. 337
Dionisi, S. 1117
Dissing, S. 1025
Djurup, R. 680
Dodds, R. A. 252
Dolitzki, M. 753
D'Onofrio, F. 1295
Donzella, C. 123
Doria, A. 785
Dorin, R. I. 46
Dorman, J. 378
Dotta, F. 1117
Dottorini, M. L. 244
Dudley, C. R. K. 948
Dukes, I. D. 877
Dunlop, M. 387, 1493
Dunlop, M. E. 298, 1131
Durola, L. 804
Dyrberg, T. 14

E

Eastman, R. 672
Ebbli, E. 306
Ebner, K. 864
Eckel, J. 764
Eckert-Norton, M. 1307
Eddouks, M. 283
Eidemak, I. 565
Eisenbarth, G. S. 1117, 1353
Eizirik, D. L. 543
Ekberg, K. 831
Ekstrand, A. V. 363
Eliasson, B. 79
Elliott, R. B. 1130
Elving, L. D. 124
Ennis, C. N. 853
Eriksson, J. 344
Eriksson, J. G. 363
Eriksson, K. F. 1466
Esposito, L. 968
Evans, S. J. W. 889, 1239
Evgrafov, O. V. 749

F

Fagrell, B. 474
Falorni, A. 1353
Farkas-Szallasi, T. 31
Fava, D. 848
Fédou, C. 494
Fedele, D. 1076
Federlin, K. 269, 656
Fedorak, R. N. 403
Fehm, H. L. 757
Feldman, B. 753
Feldt-Rasmussen, B. 565
Fennessy, M. 752
Fennessy, M. J. 1223
Fernández-Alvarez, J. 62
Ferrannini, E. 1
Ferrari, M. 968
Feskens, E. J. M. 839, 1096
Flyvbjerg, A. 135
Foley, J. E. 1213
Forsblom, C. M. 363
Forsgren, M. 1371
Fosang, A. J. 298

Fowelin, J. 79
Foyle, W. J. 356, 454
Fraser, J. R. E. 298
Fratta Pasini, A. 1122
Freire, M. B. 1486
Friemann, J. 1397
Frisk, G. 1371
Frittitta, L. 55, 445
Froguel, P. 378
Frøkjær-Jensen, J. 1025
Fu, J. 503, 1249
Fujimoto, J. 255
Fujioka, Y. 503, 1249
Fujisawa, T. 503, 983, 1249, 1494
Fukamachi, S. 1276
Fukuda, M. 503, 983
Fuller, J. H. 599
Fumelli, P. 711
Fürnsinn, C. 864

G

Gagg, J. 1482
Gale, E. A. M. 816
Gallart, T. 62
Galli-Kienle, M. 739
Gallus, G. 306
Galluzzo, A. 953, 1449
Gambardella, A. 1295
Garancini, M. P. 306
Garbin, U. 1122
Garcia de los Rios, M. 378
Gardiner, T. A. 1271
Gedulin, B. 642
Geisen, K. 269
Gelfand, R. A. 1307
Gemma, M. L. 318
Genovese, S. 816
George, E. 1183
Gessl, A. 1367
Ghirlanda, G. 848
Giaccari, A. 518
Giannoukakis, N. 715
Gillies, S. 1110
Gillmer, M. D. G. 693
Gilon, P. 879
Giordano, C. 953, 1449
Giordano, M. 732, 953, 1449
Girard, J. 283
Giroto, S. 318
Gispen, W. H. 251
Giugliano, D. 123
Going, T. C. D. 889
Gomis, R. 62
Goode, N. P. 1455
Gormley, M. 853
Gorska, J. 1443
Gothefors, L. 874
Goubet, S. 1110
Gould, G. W. 661
Gould, M. M. 1110
Gourgon, R. 726
Gower, L. F. 236
Gragoli, C. 848
Gram, J. 73
Grasso, G. 55
Gray, D. W. R. 1014
Greco, A. V. 848
Green, A. 823
Greenwood, R. H. 1055
Gries, F. A. 351, 1397, 1425
Griffin, M. 1300
Gromada, J. 1025
Grønbaek, H. 135
Groop, L. 344, 1246, 1466
Groop, L. C. 363
Gruden, G. 1218
Grzeszczak, W. 1443
Guest, P. C. 277
Günöz, H. 629
Gutierrez, L. M. 860
Gutierrez-Lopez, M. D. 378

H

Haffner, S. M. 1176, 1328
Hagura, R. 748
Hahn, A. 936
Haines, A. P. 1110
Hakalax, J. 97
Hakulinen, A. 97
Halban, P. 1375
Hales, C. N. 124, 277, 1176, 1239, 1358
Hamada, Y. 503, 983, 1249, 1494
Hamaguchi, H. 1434
Hammersley, M. S. 693
Hammes, H.-P. 269, 656
Hanafusa, T. 667
Haneda, M. 536
Hanefeld, M. 1425
Hanis, C. L. 1479
Hansen, B. 680
Hansen, B. V. 798
Hansen, F. 1082
Hanson, R. L. 187, 221, 1487
Hanssen, K. F. 1197
Hardisty, C. A. 1183
Hardy, K. J. 124
Harper, R. 853
Harris, A. 135
Harris, N. 1183
Harrison, L. C. 125
Hashimoto, N. 211
Hashiramoto, M. 193, 1489
Haslbeck, M. 1345
Hattersley, A. T. 693, 1055
Hauner, H. 764
Hawrami, K. 481
He, Q. 291, 430
Heaney, A. P. 853
Heine, R. J. 86
Hejnæs, K. R. 14
Heller, S. R. 1183
Hellerström, C. 543
Hennessy, T. R. 959
Henquin, J. C. 879
Henriksen, F. L. 326
Hermans, M. P. 253
Hermansen, K. 1069
Hetherington, C. S. 699
Heuvel, L. P. W. J. van den 161
Hibberd, M. 1495
Hibberd, M. L. 623
Hillier, C. 467
Hilsted, J. 680
Hiltunen, M. 705
Hirata, K. 1434

Hirokawa, J. 201
Hirose, H. 1276
Hitman, G. A. 481, 752, 1223
Höglinger, O. 126
Holman, G. D. 661
Holman, R. R. 948
Holst, J. J. 720
Holthuizen, P. E. 927
Hopmeier, P. 122
Horikoshi, H. 24
Houwing, H. 919
Howard, B. V. 1213, 1328
Huang, X. 1246, 1466
Hubert, P. 180
Hutton, J. C. 277
Hvidberg, A. 680
Hyllienmark, L. 685
Hyöty, H. 705

I

Ikedai, H. 772
Ikegami, H. 503, 983, 1249, 1494
Iles, R. A. 889
Inada, M. 667
Inman, L. R. 173
Ipsen, H. 680
Ipsen, M. 592
Isami, S. 422
Ishida, H. 24, 772
Ishida, Y. 193
Ishikawa, T. 649
Itakura, M. 255, 381
Ito, K. 1276
Itoh, N. 667
Ivarsson, S. A. 1371
Iwahana, H. 381
Iwoka, H. 211
Izzo, A. 306

J

Jackson, N. C. 1007
Jacobsen, N. O. 525
Jacobsson, L. T. H. 221, 1487
Jakobsen, J. 1191
James, R. W. 711
Janus, E. D. 604
Jaraquemada Pérez de Guzman, D. 876
Jarjour, I. T. 1090
Jeandidier, N. 577
Jeanrenaud, B. 998
Jenkins, D. 750
Jensen, P. K. 525
Jensen, T. 73
Jerums, G. 387, 1493
Jespersen, J. 73
Jimi, S. 1434
Jinnouchi, H. 422
Johnson, A. 1300
Johnston, G. D. 853
Jonas, J. C. 879
Jones, R. H. 1007
Jørgensen, L. N. 592
Jørneskog, G. 474
Jou, T.-S. 1490
Juliard, J. M. 726

K

Kadowaki, T. 809
 Kadrnka-Lovrenčić, M. 550
 Kahri, J. 344
 Kajimoto, Y. 585
 Kaku, K. 942
 Kalhan, S. C. 831
 Kallio, V. 487
 Kalmijn, S. 1096
 Kamada, T. 585
 Kammerer, C. M. 314, 1483
 Kanamuro, R. 809
 Kanatsuka, A. 211
 Kanazawa, Y. 748
 Kanda, F. 193
 Kande, J. 283
 Kaneko, T. 942
 Kanstrup, I.-L. 565
 Kaplan, D. L. 46
 Kaprio, E. A. 97
 Karasik, A. 753
 Karasu, Ç. 129
 Kardorf, J. 351
 Karjalainen, J. 705
 Karonen, S.-L. 106
 Kasuga, M. 193, 1489
 Katashima, R. 381
 Kato, S. 24, 772
 Katsumori, K. 792
 Kawaguchi, Y. 503, 1494
 Kawai, K. 274
 Kawakami, Y. 201
 Kawamori, R. 585
 Kawata, S. 667
 Kazumi, T. 193
 Keavney, B. D. 948
 Keegan, A. 1475
 Kekäläinen, P. 617
 Keller, C. K. 1443
 Kelley, G. G. 986
 Kemp, G. J. 1205
 Ketelslegers, J. M. 253
 Kihara, M. 914
 Kikkawa, R. 536
 Kikuchi, S. 1434
 Kimmel, P. L. 31
 Kimmerle, R. 227
 Kirsch, C.-M. 1345
 Kisanuki, K. 422
 Kishikawa, H. 422
 Kishimoto, M. 193, 1489
 Kitagawa, T. 236
 Klein, H. H. 757
 Klein, R. 437
 Klemens, C. 1397
 Klöppel, G. 1405
 Kluft, C. 73
 Knip, M. 705, 1042
 Knowler, W. C. 187, 221, 1487
 Knudsen, P. 344
 Knyazev, Yu. A. 749
 Kocova, M. 378
 Kodama, M. 585
 Kofod, H. 1025
 Kohner, E. M. 437
 Koivisto, V. A. 106
 Kokai, Y. 255
 Kolb, H. 351, 1397
 Kolb-Bachofen, V. 1397
 Kondo, T. 201

Kono, N. 667
 Kotanko, P. 126
 Kotzke, G. 757
 Kozka, I. J. 661
 Kraats, A. A. van 161, 1169
 Krarup, T. 680
 Krejs, G. J. 122
 Krolewski, A. S. 1486
 Kromhout, D. 839, 1096
 Kubota, M. 585
 Kukuvitis, A. 715
 Kullenberg, K. 216
 Kumaran, K. 831
 Kuroki, H. 792
 Kuusisto, J. 617, 1176
 Kuwajima, M. 667

L

La Greca, N. 1131
 Laak, J. A. W. M. van der 1169
 Laakso, M. 487, 617, 1176
 Lacka, B. 1443
 Lahdenperä, S. 344
 Lam, K. S. L. 604
 Lampasona, V. 816, 968
 Lampeter, E. F. 351, 1397
 Lancaster, M. E. 877
 Landau, B. R. 831
 Lapolla, A. 1076
 LaPorte, R. E. 236
 Larkins, R. G. 298
 Larsen, F. S. 14
 Launer, L. J. 1096
 Laurila, E. 1466
 Lauro, R. 445
 Lawrence, I. G. 467
 Lazzari, P. 306
 Lévy-Marchal, C. 823
 Le Beau, M. M. 1466
 Le Marchand-Brustel, Y. 1148
 Leblanc, H. 726
 Lebovitz, H. E. 1307
 Lecerf, L. 798
 Ledermann, H. M. 1482
 Lehmann, R. 1313
 Lehto, M. 1246, 1466
 Lehto, S. 487
 Leibiger, B. 112
 Leibiger, I. B. 112
 Leinikki, P. 705
 Lemieux, S. 631
 Lenti, L. 1117
 Leonetti, F. 518
 Leow, C. K. 1014
 Lernmark, Å. 1353
 Levy, J. C. 693
 Levy-Marchal, C. 370
 Li, X.-B. 1138
 Lier, H. J. J. van 124
 Lilja, B. 1003
 Lin, B. J. 1490
 Liu, Q. Z. 187
 Liu, Y. Y. 445
 Länne, T. 1082
 Lo Cascio, V. 1122
 Lobisch, M. 1425
 Lomas, J. 1412
 Longhi, R. 445
 Lorenzi, M. 785

Lounamaa, R. 705
 Love, A. 1285
 Low, P. A. 914
 Lucentini, L. 848
 Ludvigsson, J. 685
 Lund, S. 1230
 Lutale, J. 610

M

MacCluer, J. W. 314, 1483
 Macdonald, I. A. 1183, 1412
 MacDonald, M. J. 125
 Mackaay, A. J. C. 86
 MacKay, P. 145
 Mackie, A. D. R. 1055
 MacLeod, J. M. 610
 Madsbad, S. 680
 Madsen, K. L. 403
 Mäenpää, J. 97
 Maffettone, A. 1419
 Magni, F. 739
 Mahadevan, P. 298
 Majid, A. 376
 Mäkimattila, S. 555
 Makino, H. 211
 Malik, R. 874
 Malkki, M. 617
 Malmström, R. 555
 Manara, E. 306
 Mangles, D. 623
 Manhem, P. 1003
 Mannan, N. 1239
 Maran, A. 1412
 Marchello, M. J. 881
 Marco, R. de 672
 Mares, J. 153
 Marfella, R. 123
 Mariani, E. 573
 Marietti, G. 848
 Marmot, M. G. 630
 Marozzi, G. 848
 Marshall, M. O. 14
 Marshall, S. M. 610
 Martín, F. 860
 Martin, S. 351
 Maruyama, A. 792
 Maruyama, H. 1276
 Massucco, P. 936
 Masuda, K. 24
 Matsubara, A. 942
 Matsubara, H. 772
 Matsushima, H. 585
 Matsushima, M. 236
 Matsutani, A. 942
 Matsuzawa, Y. 667
 Matteoli, M. C. 848
 Matthews, D. R. 948
 Mattiello, L. 936
 Mauricio, D. 633
 Maury, J. 283
 McCance, D. R. 187, 221, 1487
 McCarthy, M. I. 481, 1223
 McKeigue, P. M. 630
 McKinlay, S. 356
 McLeish, R. 1358
 McLellan, J. A. S. 693
 McNally, P. G. 467
 Meißner, H. P. 1425
 Melamies, L. 106

Melchers, I. 351
 Menzinger, G. 804
 Mersianova, I. V. 749
 Mertz, R. J. 877
 Metcalfe, K. 752
 Metcalfe, K. A. 1223
 Metelko, Ž. 550
 Meuer, S. 437
 Michaelis IV, O. E. 31
 Miettinen, H. 1328
 Mijovic, C. 750
 Mikhailidis, D. P. 632
 Mild, T. 1249
 Millward, A. 1495
 Millward, B. A. 623
 Minei, S. 809
 Misra, A. 251
 Missler, U. 757
 Mitchell, B. D. 314, 1483
 Miura, T. 24
 Miyamoto, S. 211
 Miyamura, N. 422
 Mizuno, N. 772
 Mochizuki, H. 461
 Mogensen, C. E. 1069, 1191
 Moghetti, P. 318, 672, 1122
 Mohamed-Ali, V. 356, 1110
 Mohapatra, A. K. 251
 Moller, D. E. 757
 Montemurro, A. 445
 Monti, L. D. 739
 Monticone, G. 804
 Moody, A. J. 14
 Morales, J. 633
 Moreo, G. 573
 Morgan, R. 376
 Morris, P. J. 1014
 Morris, S. J. 1337
 Morten, K. J. 868
 Mortensen, E. 14
 Morviducci, L. 518
 Moya, F. 860
 Muggeo, M. 318, 672
 Muggli, E. 1131
 Mularoni, E. 936
 Mulder, H. 395
 Mulec, H. 216
 Multari, G. 848
 Murakami, D. 381
 Muñoz, A. 62
 Mykkänen, L. 1176, 1328
 Myrup, B. 73

N

Nagi, D. K. 187
 Naito, Y. 649
 Nakagawa, A. 262
 Nakagawa, Y. 503, 983, 1249, 1494
 Nakajima, H. 667
 Nakayama, N. 1033
 Naoumova, R. 959
 Naruse, K. 792
 Naruse, M. 792
 Nauck, M. A. 720
 Navalesi, R. 599
 Neeling, J. N. D. de 86
 Neubauer, M. 122
 Neuschuler, R. 804

Nevo

Nevo, N. 753
 Niedermann, K. 1313
 Nielsen, B. 135
 Nielsen, F.S. 592, 798
 Nielsen, J.F. 1191
 Nielsen, S. 1069
 Nielsen, S.L. 565
 Nishimura, C. 255
 Nishimura, M. 772
 Nishizawa, H. 585
 Nissinen, A. 481, 839
 Nobel, E. de 124
 Noël, M. 927
 Nolan, K.M. 889
 Noonan, K. 1239
 Norazmi, M.N. 875
 Nyberg, G. 216, 1197, 1320

O

Öberg, C. 153
 Odawara, M. 377, 1004, 1488
 Ogihara, T. 503, 983, 1249, 1494
 Ohashi, S. 274
 Ohneda, M. 173
 Okamoto, Y. 24, 772
 Olivetti, C. 1218
 Öllinger, K. 635
 Omori, Y. 792, 809
 Ongagna, J.-C. 370
 O'Rahilly, S. 868
 Orchard, T.J. 236
 Orho, M. 1246
 Orsetti, A. 494
 Ørskov, C. 720
 Ørskov, H. 135
 Osakovsky, V.L. 749
 Osei, K. 1103
 Østerby, R. 135, 1197, 1320
 Owens, D. 1300
 Oxenbøll, B. 680
 Ozanne, S.E. 277

P

Paci, F. 848
 Padma, M.V. 251
 Pagano, G. 1218
 Paillole, C. 726
 Pang, R.W.C. 604
 Paolisso, G. 1213, 1295
 Papadopoulos, G.K. 1251
 Paquis-Fluckinger, V. 1485
 Parisi, L. 804
 Parisi, V. 804
 Park, Y.H. 1138
 Parving, H.-H. 592, 798
 Pasmantier, R. 1307
 Passa, Ph. 726
 Pastore, M.R. 816
 Patanè, G. 779
 Patterson, C. 823
 Patti, L. 1419
 Pavlić-Renar, I. 550
 Pawlowski, B. 227
 Peakman, M. 875
 Pedersen, M. 680
 Pedersen, O. 481, 1230

Pekkanen, J. 839
 Pelissier, J.F. 1485
 Pennafina, M.G. 848
 Percy, A. 642
 Perez-Bravo, F. 378
 Pernini, C. 804
 Perrone, F. 848
 Petrovsky, N. 125
 Petruschke, Th. 764
 Pettermann, M. 1367
 Pettitt, D.J. 187, 221, 1487
 Pfützner, A. 351
 Phillips, D.I.W. 1205
 Pieber, T.R. 122
 Pietropaolo, M. 351
 Pilcher, C.C. 1130
 Pinget, M. 577
 Pinkney, J. 454
 Pinkney, J.H. 356
 Pipeleers, D.G. 543
 Pirisi, M. 1484
 Pisano, L. 848
 Pizzamiglio, G. 573
 Podar, T. 975
 Podestá, F. 785
 Poirier, O. 798
 Poli, F. 968
 Polychronakos, C. 715
 Poma, R. 739
 Pometta, D. 711
 Popovtzer, M. 899
 Porkka, K.V.K. 1042
 Pouget, J. 1485
 Poulsen, P.L. 1191
 Poulton, J. 868
 Powell, J.M. 413
 Pozza, G. 739
 Pozzilli, P. 126, 848
 Prašek, M. 550
 Previti, M. 1117
 Prochazka, M. 461
 Proietto, J. 1389
 Puig-Domingo, M. 633
 Pujol-Borrell, R. 876
 Pulido, N. 1262
 Purrello, F. 39, 779
 Purrello, R. 39
 Puukka, P. 487
 Puxeddu, E. 244
 Pyörälä, K. 487, 1176

Q

Quatraro, A. 123

R

Rabuazzo, A.M. 39, 779
 Radda, G.K. 1205
 Radica, A. 550
 Rafaeloff, R. 906
 Raitakari, O.T. 1042
 Ramachandran, A. 481
 Rasch, R. 525
 Rasmussen, M.H. 680
 Rasmussen, O.W. 1069
 Ratcliffe, P.J. 948
 Ravussin, E. 1213
 Raynaud, E. 494

Razzaque, M.S. 632
 Réville, Ph. 577
 Reaven, G.M. 3
 Reboldi, G. 244
 Reckless, J.P.D. 661
 Rees, A. 376
 Reig, J.A. 860
 Reinhart, L.J. 314, 1483
 Reisinger, E.C. 122
 Repetti, E. 1218
 Rewers, M. 1353
 Riccardi, G. 1419
 Richiusa, P. 953, 1449
 Ricort, J.-M. 1148
 Rigoni, A. 1122
 Rink, T.J. 642
 Ritz, E. 1443
 Ritzel, R. 720
 Rivelles, A.A. 1419
 Rizza, R. 337
 Rizzarelli, E. 39
 Robbins, D. 1328
 Roca, P. 123
 Roe, M.W. 877
 Roep, B.O. 351
 Rogge, L. 816
 Roglić, G. 550
 Röhrig, K. 764
 Romano, G. 1419
 Rönnemaa, T. 487, 1042
 Roques, M. 180
 Rosart-Ortega, F. 577
 Rösen, P. 509, 1157
 Rösen, R. 509
 Rosenberg, L. 906
 Rosenmann, E. 899
 Rossing, P. 73, 798
 Roth, T. 785
 Routsias, J. 1251
 Rovira, A. 1262
 Ruhnau, K.J. 1425
 Ruiz, J. 726
 Rump, A.F.E. 509
 Ruotolo, G. 306
 Russ, M. 764
 Russo, P. 55
 Ryan, C.M. 1090
 Ryan, I. 1307
 Rydén Ahlgren, Å. 1082

S

Saito, S. 792
 Saka, N. 629
 Sakamoto, K. 536
 Saker, P.J. 1055
 Saku, K. 1434
 Sakura, H. 809
 Samols, E. 262
 Sampson, M.J. 454
 Sanaka, M. 809
 Sanderson, A.L. 1205
 Sandler, S. 153
 Santeusano, F. 244
 Santopadre, G. 848
 Santoro, A.M. 39
 Sapin, R. 577
 Saruta, T. 1276
 Sasaki, K. 377
 Sato, T. 1033
 Sbraccia, P. 518
 Schmelzer, J.D. 914
 Schmitz, O. 565
 Schnedl, W.J. 122
 Schnell, O. 1345
 Schulte, B. 351
 Schumann, W.C. 831
 Schuster, D.P. 1103
 Schütt, M. 757
 Schütte, K. 1425
 Scionti, L. 244
 Scorsone, A. 953
 Scott, F.W. 1138
 Seino, Y. 24, 772
 Selvais, P.L. 253
 Seraglia, R. 1076
 Serrano-Rios, M. 378
 Šestan-Crnek, S. 550
 Sesti, G. 55, 445
 Shah, V.O. 46
 Shen, G. 503
 Shen, G.-Q. 1249
 Sheridan, B. 853
 Sherratt, E.J. 1482
 Shibata, M. 503
 Shichiri, M. 422
 Shigeta, Y. 536
 Shima, K. 1494
 Shimada, F. 211
 Shimizu, M. 809
 Shires, M. 1455
 Shirotani, T. 422
 Shojae-Moradie, F. 1007
 Shore, A.C. 1337
 Sigal, R.J. 1486
 Signore, A. 848
 Silvestre-Aillaud, P. 1485
 Simell, O. 97
 Simell, T. 97
 Simpson, L.O. 872
 Sipilä, I. 97
 Sirolla, C. 711
 Sivan, E. 753
 Sivieri, R. 1218
 Sjølie, A.K. 437, 599
 Skepper, J.N. 413
 Skrabal, F. 126
 Slavin, B.M. 959
 Smith, J.V. 1051
 Smith, U. 79
 Smits, P. 116
 Snehalatha, C. 481
 Somoza, N. 62
 Somville, T. 227
 Sonesson, B. 1082
 Songini, M. 1491
 Sönksen, P.H. 959, 1007
 Sorbini, C.A. 244
 Soria, B. 860
 Soulis-Liparota, T. 387, 1493
 Spencer, B. 877
 Spielman, R.S. 1479
 Spinass, G.A. 1313
 Spiro, M.J. 291, 430
 Spiro, R.G. 291
 Stagner, J.I. 262
 Standl, E. 1345
 Stassi, G. 953, 1449
 Stefani, I. 739
 Steffens, A.B. 919
 Stegmayr, B. 1061

Stemplinger, J. 1345
 Stengård, J.H. 839
 Stephenson, J.M. 599
 Stern, M.P. 314, 1328, 1483
 Stevens, E.J. 129
 Stijnen, T. 1096
 Stirling, B. 1479
 Stitt, A.W. 1271
 Stoffel, M. 1055
 Strandell, E. 153
 Strandgaard, S. 565
 Stratton, I.M. 948
 Stridsberg, M. 395
 Strödter, D. 656
 Strojek, K. 1443
 Strubbe, J.H. 919
 Suárez, A. 1262
 Sundkvist, G. 1003, 1082
 Sundler, F. 395
 Suppa, M.A. 848
 Svanberg, L. 1371
 Svendsen, I. 14
 Syed Ali, S. 269

T

Tachi, Y. 377
 Tada, K. 1004
 Tagami, S. 201
 Taguchi, T. 632
 Tai, T.-Y. 1490
 Tajima, N. 236
 Takahashi, Y. 381
 Takekawa, K. 503, 983, 1249, 1494
 Tamburrano, G. 518
 Tamura, S. 667
 Tanaka, M. 381
 Taniguchi, K. 649
 Tanizawa, Y. 942
 Tanti, J.-F. 1148
 Tantucci, C. 244
 Tao, T. 942
 Tarnow, L. 798, 1496
 Tashiro, Y. 1276
 Taskinen, M.-R. 344, 363
 Tataranni, P.A. 1213
 Taylor, D.J. 1205
 Teodonio, C. 848
 Teppo, A.-M. 363
 Tesfaye, S. 874
 Testi, R. 1449

Thien, T. 116
 Thomas, A.W. 376, 1482
 Thompson, C.H. 1205
 Thompson, C.S. 632
 Thompson, G.R. 959
 Thomsen, C. 1069
 Thurston, H. 467
 Tobin, B.W. 881
 Todaro, M. 953, 1449
 Toide, K. 1033
 Tomasini, L. 739
 Tomita, K. 667
 Tomkin, G.H. 1300
 Tomlinson, D.R. 129
 Tomonari, A. 381
 Tooke, J.E. 1337
 Torffvit, O. 525, 1492
 Tortoriello, R. 1295
 Tosi, R. 126
 Traldi, P. 1076
 Trischitta, V. 55, 445
 Trovati, M. 936
 Trucco, M. 378
 Tsuda, K. 24
 Tsuura, Y. 24, 772
 Tubes, M. 1397
 Tull, E.S. 236
 Tuomilehto, J. 481, 752, 839, 975, 1223
 Tuomilehto-Wolf, E. 481, 752, 975, 1223
 Tuominen, J.A. 106
 Turk, D. 337
 Turner, R.C. 693, 948, 1055

U

Uccioli, L. 804
 Uchigata, Y. 809
 Ueda, H. 503, 983, 1249, 1494
 Uehara, M. 422
 Uhari, M. 1042
 Uhlmann, M. 269
 Umpleby, A.M. 959
 Unger, R.H. 173
 Ura, S. 422
 Urakami, T. 748
 Urata, Y. 201
 Urbanavicius, V. 79
 Uring-Lambert, B. 577
 Usac, E.F. 62
 Utriainen, T. 555

V

Vaag, A. 326
 Valdez, R. 1328
 Van der Leest, J. 919
 Van Obberghen, E. 1148
 Van Suylichem, P.T.R. 919
 Vargas Puntí, M.D. 445
 Varricchio, M. 1295
 Veerkamp, J.H. 161
 Vela, B.S. 46
 Velasquez, M.T. 31
 Vergani, D. 875
 Verlato, G. 318, 672
 Vestergaard, H. 1230
 Veves, A. 1051
 Vialettes, B. 1485
 Viberti, G.C. 252, 599, 1197, 1320
 Vigneri, R. 39, 779
 Viikari, J.S.A. 1042
 Vinci, C. 39
 Vine, W. 642
 Vinik, A.I. 906
 Virtala, E. 975
 Visalli, N. 848
 Viswanathan, M. 481
 Viñas, O. 62
 Vokac, A. 1313
 Voldsgaard, A.I. 592
 Vries, H. de 86

W

Wagner, L. 1367
 Wagner, R. 351
 Wahren, J. 831
 Wakisaka, M. 291
 Walbank, H. 1475
 Wald, H. 899
 Waldhäusl, W. 864, 1367
 Walker, J.D. 252, 1197, 1320
 Walker, M. 699
 Walker, M.G. 1051
 Wang, R.N. 1405
 Ward, J.D. 874
 Wareham, N.J. 1358
 Warley, A. 413
 Warren-Perry, M. 1055
 Wasada, T. 792
 Watanabe, Y. 274, 792
 Watt, M.J. 1285

Watt, P.A.C. 467
 Watts, G.F. 959
 Weiss, A. 269, 656
 Welsh, M. 153
 Welsh, N. 153
 Westermarck, P. 543
 Wetzels, J.F.M. 124
 Williams, D.R.R. 1358
 Williams, S.C.R. 889
 Wollmer, P. 1082
 Worley III, J.F. 877
 Wu, H.-P. 1490

Y

Yamada, T. 255
 Yamagata, K. 667
 Yamaoka, T. 255
 Yamasaki, Y. 585
 Yamashita, K. 255, 274, 377, 1004, 1488
 Yamato, E. 503, 983, 1249, 1494
 Yanagisawa, K. 809
 Yasuda, K. 772
 Yki-Järvinen, H. 555, 1378
 Yokota, C. 274
 Yoon, J.-W. 1138
 Yoshida, K. 201
 Yoshida, S. 211
 Yoshimoto, K. 381
 Young, A.A. 642
 Young, M.J. 1051
 Yu, L. 1353
 Yudkin, J.S. 356, 454, 1110

Z

Zager, P.G. 46
 Zaß, R.-P. 227
 Zawalich, W.S. 986
 Zenere, M. 318
 Zenti, M.G. 1122
 Zerbini, G. 785
 Zhang, H. 635
 Zhang, Y. 1055
 Ziegler, D. 1425
 Zoppini, G. 318
 Zorretta, D. 518

Subject Index

KEY: A = Abstract in Supplement 1; b = Book review; c = Correspondence; r = Review or Debate; w = Workshop report

A

A-cell, islet – insulin receptor 422
 Acetyl carnitine – nerve, effect on A 7, A 8
 Acetylcholine – islet cell function, effect on – diabetic rat 1276
 Adenosine deaminase – gene – MODY not linked 1055
 Adhesion – kinase – focal – glomerular – diabetic rat 1131
 – molecule – diabetes, serum levels in 1122
 – intercellular 1122
 – – endothelial cell – glucose, effect of 1367, A 53
 – – microalbuminuria and A 211
 – – serum – Type 1 diabetes A 260
 – – – Type 2 diabetes A 41
 – platelet – endothelial cell, expression by – glucose effect 1367
 – soluble – E-selectin – diabetes, serum levels in 1122
 – vascular 1122
 Adipocyte [see also Fat; GLUT]
 – glucose transport – chronic insulin exposure, effect of 1148
 – human vs rat 661
 – human – cultured 764
 – insulin receptor – signalling 1148
 – insulin resistance – insulin-induced 1148
 – insulin sensitivity – regional variation A 141
 – lactate production A 12
 – non-esterified fatty acid release A 144
 – tumour necrosis factor, effect of 764
 Adipose tissue [see Fat]
 Adrenoceptor – β_2 – expression – salt sensitivity, reduced in 126c
 – β_3 – gene – insulin resistance and A 35
 – expression – islet – measurement A 130
 Adrenomedullin A 108
 AGE [see Glycation – advanced end-product]
 Age – islet B-cell, changes in A 94
 – old – cognitive function and glucose tolerance 1096
 Ageing – glucose transport, effect on – rat adipocyte A 134
 – islet, effect on A 107
 Albert Renold Fellowship 1995 – Paola Fioretto *EASD News Section 10/95* 43
 Albumin excretion rate – blood pressure and – NIDDM 356
 – children of Type 2 diabetic patients 1218
 – diabetic retinopathy and – blood pressure and 599
 – diurnal variation A 213
 – glomerular heparan sulphate and – diabetic rat 161
 – heritability A 63
 – hyperinsulinaemia, effect of A 149
 – octreotide, effect of – diabetic rat 135
 Alcohol – abuse – diabetic autonomic neuropathy and A 240
 – peripheral vascular disease and A 268

Aldose reductase – diabetic nephropathy, role in – rat 387
 – erythrocyte vs nerve levels A 237
 – expression – kidney – galactose-fed rat 46
 – human – transgenic mouse, effects in 255
 – inhibitor – diabetic neuropathy A 237
 – – experimental neuropathy, effect on A 232
 – ponalrestat – experimental nephropathy 387
 – therapy – long-term A 47
 – tolrestat A 237
 – vascular reactivity, effects on – ponalrestat vs sorbinil A 255
 – zopolrestat – vascular reactivity, effect on A 262
 Alkali – infusion – bicarbonate plus carbonate 889
 Alloxan – insulin-secreting cell toxicity – oxidative stress, role of 635
 Amino acid – insulin secretion, effect on A 101, A 102
 – transporter – islet B-cell A 111
 Aminoguanidine – diabetic nephropathy, effect on – rat 387
 – diabetic retinopathy, failure to prevent – rat 269
 – islet B-cell, effect on A 95
 – islet glucotoxicity, effect on A 93
 – nerve, effect on – diabetic rat A 233
 – renoprotective effect A 47
 – therapy – diabetic retinopathy – diabetic rat 656
 – treatment – vascular reactivity, effect on A 262
 – vascular proliferation, effect on – diabetic rat A 255
 Amputation – diabetes A 271, A 272
 Amylin – amyloid formation – human islet xenograft in nude mouse 543
 – analogue – AC137 – metabolic effects A 193
 – – IDDM, use in A 44
 – – gastric emptying, effect on A 32
 – antagonist – GI150747A – insulin secretion, effect on A 113
 – cytotoxicity? A 91
 – gastric emptying, effect on – diabetic BB rat 642
 – expression – insulin expression compared 395
 – gestational diabetes, in A 282
 – insulin resistance, role in – NIDDM families A 152
 – kidney, binding in – juxtaglomerular apparatus A 131
 – processing A 92
 – regulation A 92
 – renin-angiotensin system, effect on A 225
 – secretion – pro-amylin cleavage A 27
 Amyloid, islet – apolipoprotein E, role of A 27

– human islet transplanted to nude mouse 543
 Angiotensin – converting enzyme – inhibitor – captopril 509
 – – diabetic nephropathy A 206, A 218–A 221
 – – glucose transport, enhancement of A 142
 – – microvascular effect – diabetes A 49
 – – myocardial perfusion, effect on 509
 – – diabetes, use in A 46, A 47, A 226
 – – retinal vascular effects A 277
 – polymorphism – coronary heart disease 798
 – – diabetic complications and 798, A 227
 – – myocardial infarction 948
 – II – islet, effect on A 92
 – receptor polymorphism – complications of diabetes and A 228, A 229
 Anorexia nervosa – proinsulin binding A 128
 Anti-lipolytic drug [see Lipolysis – inhibitor]
 Antibody – advanced glycation end-products A 161
 – auto – Type 1 diabetes – twin study A 43
 – autonomic nerve – Type 1 diabetes A 240, A 241
 – GAD A 54, A 87, A 88
 – 69 – prediction of Type 1 diabetes 816
 – assay – ELISA A 6
 – CD95 expression and A 17
 – diabetic neuropathy and A 240
 – epitopic specificity A 90
 – immunosuppressive therapy, effect of A 100
 – NIDDM, in A 78
 – pregnancy, in – subsequent diabetes A 70
 – ganglioside – diabetic neuropathy and A 240
 – GM2 A 6, A 90
 – insulin [see Insulin – autoantibodies; Insulin – immunogenicity]
 – islet-cell – 37kD – prediabetes Type 1 370
 – – tryptic fragments 816
 – – 69 351, 816
 – antigen specificity and prediction of Type 1 diabetes 816
 – assay – immunofluorescence – quality control 633 C
 – – time-resolved fluorescence imaging A 6
 – B-lymphocyte subsets, release by 62
 – cord blood – Sardinia A 86
 – immunotherapy, effect of A 100
 – inheritance – parental gender and 1353
 – prediction of Type 1 diabetes 816
 – protein tyrosine phosphatase – IDDM A 5
 – relatives of Type 1 diabetes – gender A 87

- - seroconversion - Epstein-Barr virus serology 1130c
- - subtotal pancreatectomy, induced by 1397
- oxidised LDL - atherosclerosis and A26
- phospholipid - diabetes - Type 1 A257, A258
- tyrosine kinase - Type 1 diabetes - family study A42
- Antidepressant - glucose homeostasis, effect on A205
- Antigen - islet-cell - 37kD - protein tyrosine phosphatase A5, A86
- - 38kD - cloned A37
- - 51kD - aromatic L-amino acid decarboxylase A5, A129
- - GAD65 - tolerance induction A98
- - ganglioside - GM2-1 - characterisation 1117
- - molecular mimicry - GAD and α 2-macroglobulin 874c
- - p69 - bovine serum albumin mimicry A16
- presentation - TAP peptide transporter gene 968
- Antioxidant - butylated hydroxytoluene 387
- diabetic neuropathy, effect on - streptozotocin-diabetic rat 1285
- lipoic acid - therapy - diabetic neuropathy 1425
- - nicotinamide - streptozotocin-diabetic rat A98
- - phenylsuccinyl - streptozotocin diabetes prophylaxis A97
- - probucol 387, 129
- Vitamin E - heart, effect on in diabetic rat 1157
- - vascular reactivity, effect on in diabetic rat 1475
- Apolipoprotein [*see also* Lipoprotein/
- (a) - LDL bound [*see* Lipoprotein - (a)]
- - polymorphism - lipoprotein (a) levels and 1434
- B - haemodialysis, effect of in diabetes A162
- CII - triglyceride level and A25
- E - polymorphism - diabetic nephropathy progression and A209
- Apoptosis (Programmed cell death) - insulin-secreting cell A38
- islet cell - G-protein, role of A45
- T lymphocytes - Type 1 diabetes 953
- triggering receptor CD95 - lymphocytes, T&B - Type 1 diabetes 1449
- Artery - carotid - wall thickness and impaired glucose tolerance 585
- compliance - diabetes, sex differences in 1082
- - ultrasonic echo-tracking 1082
- Atrial natriuretic peptide - glomerular hyperfiltration, role in 536
- plasma - diabetes 1443
- receptor - inhibitor - HS-142-1 536
- Audit - clinical [*see* Peer review/
- Auditory function - diabetic neuropathy and A236
- Autoimmunity - molecular mimicry as a factor 874c
- polypeptide Type 1 - aromatic L-amino acid decarboxylase A129

B

- B-cell, islet [*see also* Islet; Insulin - secreting cell; Insulin - secretion/
- age-related changes A94
- Ca^{2+} A115-A121
- - insulin release by - permeabilised GK rat islet 772
- - $\text{Na}^+/\text{Ca}^{2+}$ exchanger A27
- - repaglinide, effect of 1025
- cDNA library - random sequencing - insulin-secreting cell 381
- cytotoxicity - IGF-1, protective effect of A80
- - nitric oxide in A81, A82
- diabetes - Type 2 3r
- function - diabetes - Type 1 - age, effect of 97
- G protein 779
- GLP-1 receptor 274
- glucagon receptor 274
- glucotoxicity - glucosamine, role of 518
- GLUT 2 expression - calorie restriction, effect of - *fa/fa* rat 173
- glycolysis A95
- injury - interleukin 1β vs nitric oxide 153
- - man vs rat A45
- - nitric oxide vs oxygen radicals A81
- ion flux - hypoglycaemic agents, effects of 1025
- K^+_{ATP} channel - repaglinide, effect of 1025
- - troglitazone, unaffected by 24
- Kearns-Sayre syndrome, in 868
- maturation - neonatal rat A65
- MHC expression - Class I - BB rat 1138
- neogenesis from duct cell - duct-ligated adult rat 1405
- signal transduction A115-A125
- syntaxin 860
- total volume, regulation of A85
- Biguanide [*see* Metformin/
- Bladder, urinary - function - sodium pump activity A234
- Blood - flow [*see also* Vascular - reactivity/
- - brain - diabetic autonomic neuropathy A239
- - - hypoglycaemia, effect of 1090
- - Doppler ultrasonography 555
- - insulin, effect of 555, A49
- - nerve 129,
- - skeletal muscle - bradykinin, effect of A49
- - - hyperinsulinaemia, effect of A50
- - - skin - endothelial role A157
- - - laser Doppler study 555, 1337
- - venous occlusion plethysmography 555
- group - Lewis A78
- pressure - albumin excretion rate and - EURODIAB Study 599
- - ambulatory monitoring - albumin excretion rate and 356
- - - diabetic nephropathy 216
- - - IDDM A212, A213
- - - microalbuminuric Type 2 diabetes 1069
- - exercise, effect of - NIDDM 1313
- - microalbuminuria and A212
- - salt sensitivity - diabetes 1443, A214
- Body composition - diabetic rat - islet transplantation effect 881

- Type 1 diabetes A150
- Bone - metabolism - diabetes A185
- ultrasonography A185
- Bradykinin - glucose uptake, effect on A49
- Brain [*see also* Cognitive function/
- blood flow - diabetic autonomic neuropathy A239
- - hypoglycaemia, effect of 1090, A204
- cerebrovascular disease [*see* Stroke/
- function - NIDDM 251c
- glucose uptake - insulin, effect of A203
- perfusion - ^{123}I -iodoamphetamine single-photon emission CT 1004c
- - MELAS, in 1004c
- Breast feeding - glucose tolerance in adult life and A61
- BRLP-42 [*see* Hypoglycaemic agent/

C

- C-peptide - renal effects - Na^+/K^+ ATPase, role of A64
- treatment - diabetic autonomic neuropathy A238
- treatment - IDDM A7
- Cachexia - tumour necrosis factor, role of? 764
- Calcium - channel - blocking agent - albumin excretion, effect on A219
- - - nifedipine - diabetes A219
- - - verapamil - ACE inhibitor, with A142
- - subunits - insulin-secreting cell A115, A116
- GLP-1 action, requirement for A169
- islet B-cell [*see* B-cell, islet; Insulin - secretion/
- Capillary - blood cell velocity - diabetes 467
- density - skin - Type 2 diabetes A262
- myocardial - streptozotocin-diabetic rat 413
- permeability - glucose - insulin-sensitive transport in A149
- - diabetes A216, A262
- Cardiolipin antibody [*see* Antibody - phospholipid/
- Cardiovascular - reflex testing A242
- risk factor - ACE polymorphism in diabetes 948
- - adverse - childhood hyperinsulinaemia predicts 1042
- - albumin excretion rate and - Type 2 diabetes A222
- - carotid artery wall thickness 585
- - diabetes, interaction with 487
- - diabetic nephropathy, in 798
- - epidemiology A223
- - exercise, effect of - NIDDM 1313
- - gender, effect of A224, 1082
- - hyperinsulinaemia and - specific insulin assay 1110
- - lipoprotein (a) 711, A251
- Carnitine - diabetic neuropathy 123c
- nerve, effect on in diabetic rat A233
- Carotene - β [*see* Antioxidant/
- Castello Pedrollo Prize 1995 - Rudiger Landgraf EASD News Section 10/95 42
- Cataract - lycopene, inhibition by A276
- thioctic acid, protection by A276

Catecholamine

- Catecholamine – hypoglycaemia, response to 1183
- insulin receptor expression, effect on A 131
- islet cell function, effect on – streptozotocin-diabetic rat 1276
- plasma – hyperinsulinaemia. effect of A 140
- Cell-death, programmed *[see Apoptosis]*
- Cellophane wrap – hamster pancreas – islet regeneration model 906
- Cerebral *[see Brain]*
- Chaos theory – heart rate variability A 241
- Charcot foot A 272
- Cholecystokinin – insulin secretion, stimulation of A 124
- Cholesterol *[see also Dyslipidaemia; Hypercholesterolaemia; Lipoprotein]*
 - ester transfer – Type 2 diabetes A 249
 - synthesis – hyperinsulinaemia and A 248
 - mevalonic acid as marker 959
 - obesity A 159
 - Type 2 diabetes A 248
- Chorionic gonadotrophin – retinal vascular cells, effect on A 275
- CIGMA (continuous infusion of glucose with model assessment) *[see Insulin – secretion]*
- Clofazone *[see Phosphodiesterase inhibitor]*
- Cisapride – gastric emptying, effect on – diabetes A 245
- Clamp *[see also Glucose; Insulin – secretion]*
 - euglycaemic hyperinsulinaemic – glucosamine effects 518
 - insulin sensitivity measurement A 127
 - labelled glucose 699
 - limb blood flow 555
 - glycerol A 149
 - hyperglycaemic – glucosamine effects 518
 - non-esterified fatty acid – childhood obesity 739
 - stepped hypoglycaemic 1412
- Claude Bernard Lecturer 1995 *EASD News Section 10/95 45*
- Coagulation, anticoagulation *[see Haemostasis; Endothelial; Fibrinolysis]*
- Coeliac disease – screening test in IDDM A 51
- Cognitive function – diabetes – Type 2 251 c
 - glucose tolerance and, in elderly men 1096
 - hypoglycaemia, during 1412
 - monitoring – hypoglycaemia, during A 204
- Collagen – endothelial cell, formation by – rat heart 430
 - expression – diabetic nephropathy 632 c
 - IV – glomerular basement membrane – diabetic nephropathy 1455
- Colon *[see Intestine]*
- Colour vision – tritan discrimination sensitivity – diabetes A 277
- Complications of diabetes – aldose reductase, role of 255
 - angiotensin-II receptor polymorphism A 228, A 229
 - angiotensin converting enzyme polymorphism A 227, A 228
 - EURODIAB Study 599

- Computer – autonomic function testing A 241, A 242
 - insulin dose adjustment A 186
- Contraceptive – intrauterine – diabetes – Russia A 282
- Copper – islet, effect on – interleukin 1 β , protection against 39
- Cori cycle – diabetes – Type 2 326
- Cushing's disease – hyperinsulinaemia in – β -endorphin role A 112
- Cyclic nucleotides – vascular smooth muscle 936
- Cystic fibrosis – glucose tolerance A 13
- Cytochrome – P450 – CYP1A – islet, expression in A 135
- Cytoskeleton – insulin action, effect on A 138

D

- Darglitazone *[see Hypoglycaemic agent – thiazolidinedione]*
- Death – cell – programmed *[see Apoptosis]*
- Diabetes – care – France A 25
 - genetic syndrome – Kearns-Sayre syndrome 868
 - gestational A 280, A 282
 - borderline – outcome A 71
 - glucose tolerance in parents 693
 - mitochondrial gene, mutant, in 809
 - multiple pregnancy A 36
 - outcome of previous pregnancies A 71
 - prognosis A 70
 - screening criteria A 36, A 71
 - heterogeneity A 60
 - maturity-onset in youth *[see MODY]*
 - Type 1 – aetiology & pathogenesis A 16
 - age at onset – genetic heterogeneity 623, A 29
 - autoimmunity – CD95 expression, role of 1449
 - childhood – residual islet B-cell function 97
 - disease-modifying therapy A 97–A 100
 - BCG (Freund's adjuvant)? 873 c
 - diet – BB rat model 1138
 - intensive insulin therapy A 51
 - nicotinamide 848
 - genetic heterogeneity A 89
 - infancy A 89
 - infection, role of *[see also Diabetes – Type 1 – Virus]*
 - infantile infection, protection by A 99
 - BCG vaccination 873 c
 - remission – spontaneous A 100
 - susceptibility – HLA-matched controls 125 c
 - virus, role of – CMV 667, 705
 - Coxsackie B – maternal infection 1371
 - EBV 667, 1130 c
 - Type 2 – animal model – Cohen diabetic rat 899
 - NSY mouse 503
 - environmental factors 1125 r
 - epidemiology – Italy 306
 - insulin resistance, role of 992 r, 1378 r
 - insulin secretion in 986 r, 992 r
 - islet B-cell, role of 986 r

- pathophysiology 3 r
- prevention 1125 r
- Vitamin D repletion? 1239
- treatment *[see also Diet; Exercise; Hypoglycaemic agent; Sulphonylurea]*
 - UK Prospective Diabetes Study A 24
- Diacylglycerol-protein kinase C pathway – vascular reactivity A 261
- Diazoxide – derivative – BPDZ44 and BPDZ62 – islet B-cell effect A 124
- Diazoxide – Type 1 diabetes – disease-modifying therapy A 99
- Diet A 177 – A 178
 - calorie-restricted – islet B-cell GLUT-2 expression, effect on 173
 - diabetogenic – BB rat 1138
 - fat – essential fatty acid deficient – insulin secretion, effect on A 107
 - monounsaturated – microalbuminuric Type 2 diabetes, in 1069
 - postprandial insulin precursor secretion, effect on A 113
 - unsaturated – ω -3 253 c, A 214
 - fructo-oligosaccharides – glucose production, effect on A 148
 - infancy – overfeeding – insulin resistance syndrome following A 166
 - protein – diabetic nephropathy A 216
 - high – diabetic nephropathy and – BB rat A 207
 - hepatic glycogen synthesis, effect on A 148
 - low – pregnancy A 280
 - sucrose – insulin secretion, effect on – rat A 101
 - SHR/N-cp rat – glomerulopathy 31
- DNA – complementary – insulin-secreting cell library 381
- Dupuytren's contracture – Type 1 diabetes A 187
- Dyslipidaemia *[see also Cholesterol; Hypercholesterolaemia; Hypertriglyceridaemia; Lipoprotein; Triglyceride]*
 - diabetes – Type 1 – black Africans A 246
 - Type 2 3 r
 - treatment A 250

E

- EASD – 30th anniversary *EASD News Section 4/95*
- 30th General Assembly, Dusseldorf, 1994
 - abstracts (Suppl 1) A 3–A 285
 - Erratum. *EASD News 10/95 47*
 - Author Index A 287
 - minutes (Suppl 1) I
- Scientists Training Course *EASD News Section 11/95 49 w*
- Study Group – AIDSPIT (Artificial Insulin Delivery Systems, Pancreas & Islet Transplantation) – *EASD News Section: 8/95 29 w*
- Diabetic Nephropathy *EASD News Section 9/95, 35 w*
- Hypertension *EASD News Section 11/95 51*
- Psychosocial Aspects of Diabetes *EASD News Section 7/95*
- ECG *[see Heart – ECG]*
- Education – diabetes A 24, A 180–A 182

- EKG, Electrocardiogram [see Heart - ECG]
- Electrofusin A 108
- Eli Lilly/EASD Research Fellowship 1995 *EASD News Section 10/95 44*
- Embryo/Fetus [see also Pregnancy]
- Cocksackie B virus and subsequent Type 1 diabetes 1371
- Embryopathy A 281
- diabetic A 21
 - - butylated hydroxytoluene, amelioration by A 22
- Encephalopathy - diabetic 1191
- Endopeptidase - PC₂ (proinsulin convertase 2) A 105
- Endorphin - hyperinsulinaemia, role in - obesity & Cushing's d. A 112
- Endothelial, Endothelium - acetylcholine, effect of - IDDM A 48
- - adhesion molecule expression - glucose, effect of 1367
 - - apoptosis - glucose triggered A 254
 - - endocytosis - glucose, effect of 1271
 - - fibronectin - glucose, effect of 785
 - - - expression - protein kinase C, role of A 116
 - - glycation, effect of 1271
 - - heart - matrix formation - glucose, effect of 430
 - - Na⁺/H⁺ antiport - glucose, effect of 785
 - - oxidative stress, effect of - mitochondrial gene deletion A 261
 - - replication - glucose, effect of 785
 - - von Willebrand factor secretion A 253
 - - corpus cavernosum - diabetes A 238
 - - function - hyperglycaemia, effect of - IDDM A 150
 - - insulin transport - receptor-mediated A 189
 - - nitric oxide production - L-arginine, effect of A 48
 - - skin vasodilatation, role in A 157
 - - tissue factor pathway inhibitor - diabetes A 53
 - - Vitamin E, protection by 1475
- Endothelin - complications of diabetes A 264, A 265
- - insulin secretion, effect on A 105
 - - plasma - ω -3 fatty acids, effect of 253c
 - - Type 2 diabetes, lack of effect in A 48
- Energy metabolism - diabetes - islet transplantation, effect of 919
- Enterostatin - insulin secretion, effect on A 15
- Epidemiology - cardiovascular risk factors A 223
- - diabetes A 172-A 176
 - - - Italy 306, 318
 - - - MODY - central Europe 1482c
 - - - renal mortality - Japan vs Pennsylvania, USA 236
 - - - Type 1 - age at diagnosis 823
 - - - - Chile 378c
 - - - - Croatia 550
 - - - - EURODIAB ACE study 823
 - - - - risk & birth cohort 975
 - - - - seasonality 823
 - - - - sex difference 975
 - - - - southern Europe 1491c
 - - fibrinogen, plasma - cardiovascular risk factors and A 164
 - - impaired glucose tolerance - cardiovascular risk factors and A 164
 - - insulin resistance - African Americans - resident vs immigrant 1103
 - - macrovascular disease - Hoorn study 86
 - - nephropathy, diabetic A 215
 - - retinopathy, diabetic A 57
 - - stroke - diabetes 1061
- Erectile failure - diabetes A 238
- Erythrocyte - deoxygluconic acid A 161
- - diabetes - human vs streptozotocin-diabetic rat 872c
 - - diabetes - Type 2 - pravastatin, effect of A 258
 - - glycogen synthesis as well as glycolysis A 142
 - - membrane composition - obesity A 159
 - - osmotic shock ATP release - diabetes, defective in A 258
- EURODIAB complications study - diabetic nephropathy 599
- - retinal photography 437
- European - Association for Study of Diabetes [see EASD]
- Exendin - (9-39) - GLP-1 receptor antagonist 274, A 169, A 170
- Exercise A 179 - A 182
- - acute - capacity - chronic renal failure 565
 - - - - diabetic neuropathy, effect of A 52
 - - - - cardiovascular response - diabetic autonomic neuropathy 244
 - - - - diabetes - Type 2 - hypoglycaemia 106
 - - - - energy metabolism - diabetes 919
 - - - - glycogen-depleting - insulin sensitivity following A 50
 - - training - blood-flow, insulin-stimulated A 34
 - - - - diabetes - Type 2 1313
 - - - - NIDDM A 24
- Exocytosis [see Insulin - secretion]
- Eye [see Cataract, Colour vision, Lens, Pupil, Retina, Retinopathy, Visual]
- F**
- FAD-glycerophosphate dehydrogenase - lymphocyte - gest. DM A 282
- - mitochondrial - Type 2 diabetes A 77
- Family study - diabetes - gestational - glucose tolerance in parents 693
- - - Type 1 A 87-A 90
 - - - - GAD antibody A 54, A 55
 - - - - islet-cell antibodies 370, 1353
 - - - - prediabetic CMV? 705
 - - - - recurrence risk - gender 975
 - - - - Type 2 - albumin excretion rate 1218
 - - - - - insulin sensitivity and A 221
 - - - - - impaired glucose tolerance in young relatives A 151
 - - - - insulin resistance and microalbuminuria 363
 - - - - insulin secretion A 112
 - - - - islet B-cell function A 12
 - - - - lipoprotein (a) and apolipoprotein (a) types 1434
 - - - - lipoprotein abnormalities A 249
 - - - - maternal transmission? 314, 1482c
 - - - - Na⁺/H⁺ antiport activity A 230
 - - - - parental nephropathy as risk factor 221, 1486c
- Fat [see also Adipocyte]
- - abdominal - Otsuka Long-Evans Tokushima Fatty Rat 1033
 - - distribution [see also Obesity] - hyperinsulinaemia and A 164
 - - glucose turnover - GLP-1 (7-36 amide), effect of A 170
 - - insulin receptor tyrosine kinase activity 55
 - - mass - diabetic rat - islet transplantation effect 881
 - - regulation - NIDDM 3r
- Fatty acid - essential - diabetic nerve, effect on 129
- - infusion - Intralipid - insulin secretion, effect on 1285
 - - - glucose 6-phosphatase, inhibition of A 144
 - - - glucose tolerance test, suppression in 1358
 - - - insulin secretion, effect on - duration of infusion 1285
 - - - islet B-cell, effect of A 96
 - - - serum - exercise, effect of - diabetic rat 919
 - - - - NIDDM 3r
 - - - - prediabetes Type 2 1213
 - - unsaturated - insulin secretion, effect on A 106
 - - - ω -3 - endothelin-1, plasma, effect on 253c
 - - - - lipogenic enzyme expression in hHTg rat, effect on A 146
- Fetus [see Embryo/Fetus]
- Fibrinogen [see Haemostasis]
- Fibrinolysis - diabetes - pregnancy A 285
- - impaired glucose tolerance, in A 52
 - - oxidative stress and - diabetes A 252
 - - Type 2 diabetes A 256
 - - - family study A 52
- Fibroblast - senescence - diabetic nephropathy, in A 206
- Fibronectin - endothelial cell expression 785
- - - rat heart 430
- Fitness, physical [see Exercise - training]
- Flow cytometry - T lymphocytes 953
- Foetus [see Embryo/Fetus]
- Foot - diabetic A 271-A 274
- Freedom Editorial 1
- Fructose - bisphosphatase, 1-6 - hepatic - diabetic NZO mouse 1389
- - insulin secretion, stimulation of A 102
- G**
- G protein - apoptosis, role in A 45
- - islet B-cell, role in 779
 - - subunits - islet cells, distribution in A 116
- GAD [see Glutamic acid - decarboxylase]
- Gait A 272
- Galileo Galilei Editorial 1
- Gall bladder - hyperglycaemia, effect of A 156
- Ganglioside - islet - GM2-1 1117
- Gas chromatography mass spectrometry 959
- Gastric - bypass surgery - obesity & NIDDM, effect on A 158
- - emptying A 244, A 245, A 31, A 32

Gastrin

- - amylin, effect of - diabetic BB rat 642
- - assessment - $3\text{-}^3\text{H}$ glucose gavage - rat 642
- - diabetic ketoacidosis, impaired in - fatty acids, role of 632c
- - GLP-1, effect of A39
- - hyperinsulinaemia, effect of 79
- Gastrin - diabetic gastroenteropathy - cisapride therapy A245
- releasing peptide (GRP) - insulin-secreting cell, effect on A119
- Gastrointestinal - function A244-A246
- motility - hyperinsulinaemia, effect of 79
- Gastroplasty - obesity, in A158
- Gene - cDNA library - insulin-secreting cell 381
- mitochondrial [see also Maternally-inherited diabetes with deafness]
- - diabetes - Type 2 - pregnancy outcome 809
- - endothelial cell - oxidative stress, deletion induced by A261
- - - Kearns-Sayre syndrome 868
- - - mutation - diabetes 193, A229
- - - gestational diabetes 809
- - - methods 376c, 377c
- - - non-diabetic kidney disease A229
- - - Type 2 diabetes A34, A75, A76
- - - - cerebral perfusion 1004c
- - reg - expression - regenerating hamster islets 906
- - regulation - GLUT 2 112
- - TAP (antigen processing transporter) - Type 1 diabetes A72
- transfection - islet cells A28
- Genetics [see also Family study, HLA, Inheritance, Polymorphism]
- complications of diabetes A227-A230
- diabetes - Type 1 A28, A72
- - - 30th Minkowski Lecture *EASD News Section 10/95 39*
- - - CD4 linkage A29
- - - CTLA4 microsatellite A29
- - - heterogeneity - age at onset 623, 748c
- - - HLA [see also HLA] - DR 1251
- - - susceptibility vs heterogeneity 1493c
- - - Ins-IGF2 - parental imprinting 715
- - - insulin gene - HLA interaction 1223
- - - interferon γ A29
- - - TAP2 gene 968
- - - Type 2 A34, A74
- - - adenosine deaminase gene not linked 1490c
- - - glucagon receptor gene 975, 1246
- - - GLUT-2 polymorphism 942
- - - glycogen synthase gene 1249c
- - - hexokinase gene 1466
- - - insulin receptor substrate-1 gene 481
- - - linkage study - Japanese A35
- - - maternal inheritance 314, 1482c
- - - MODY 1055
- - - sulphonylurea receptor gene not linked 1479
- - insulin resistance - Pima Indians 461
- - twin study A140
- MODY 1055, A60
- GIP - receptor - expression - islet B-cell A131
- Glicentin - recombinant - actions A130
- Glomerular - basement membrane - charge - diabetic nephropathy 1169
- - chondroitin sulphate proteoglycans 1455
- - diabetes - heparin, effect of A62
- - diabetic nephropathy 1455
- - heparan sulphate - diabetic rat 161
- - - associated anionic sites 1169
- - electron microscopy - stereology 1197
- epithelial cell - foot processes - Type 1 diabetes 1197
- filtration rate - measurement 252c
- - NIDDM A215
- filtration slits - Type 1 diabetes 1197
- filtration surface area - age at diagnosis of IDDM and A209
- focal adhesion kinase - streptozotocin-diabetic rat 1131
- function in diabetes - *myo*-inositol feeding, effect of 899
- hyperfiltration - atrial natriuretic peptide role? - diabetic rat 536
- juxtaglomerular arterioles - IDDM 1320
- mesangial cell - glucose transport - rat 291
- - hyaluronan production - diabetic rat 298
- - IGF-I activity - glucose, effect of A62
- - morphometry - juxtaglomerular arterioles - IDDM 1320
- - SHR/N-cp rat 31
- - streptozotocin-diabetic rat 135
- - Type 1 diabetes A210
- GLP (Glucagon-like peptide)
- GLP-1, GLP-1 (7-36 amide) A167-A172
- glycogenesis, no effect on in skeletal muscle 864
- hypoglycaemic effect *Erratum, EASD News Section 10/95 47*
- insulin-secreting cell, effect on - desensitization A117
- receptor - expression - islet B-cell A131
- therapy - pharmacokinetics 720
- - Type 1 diabetes A40
- - Type 2 diabetes A39
- insulin secretion, effect on A40
- receptor - gene - MODY not linked 1055
- - inhibitor - exendin (9-39) 274
- - islet B-cell 274
- Glucagon - myocardium, effect on A129
- pancreatic acinar cells, binding to 262
- postprandial suppression - Type 1 diabetes, lacking in 337
- protein metabolism, regulatory role in A23
- receptor - expression - islet B-cell A131
- - gene - diabetes - Type 2 975, 1246
- - islet B-cell 274
- secretion - GLP-1 (7-36 amide), effect of 720
- - hypoglycaemia, during - neural mediation A203
- - insulin-stimulated 422
- - neurotransmitters, effect of - streptozotocin-diabetic rat 1276
- sensitivity - hypoglycaemia, following A202
- Glucagon-like peptide [see GLP]
- Glucocorticoid - bone fibroblast, effect on A125
- islet B-cell cytotoxicity, protection against A80
- islet B-cell, effect on - amylin & insulin expression 395
- neuropeptide Y expression induction in rat islets A147
- pulse - glucose intolerance following A149
- receptor - islet B-cell A128
- Glucokinase - gene - islet B-cell A15
- - MODY 1055, A60
- - regulation - insulin-secreting cell A115
- insulin-secreting cell - pregnancy hormones, effects of A145
- islet - glucose, regulation by A96
- - anomeric specificity A76
- - translocation after glucose stimulation A107
- recombinant human - kinetics of isoforms A28
- regulatory protein - rat models of Type 2 diabetes A146
- Gluconeogenesis - diabetes - lipolysis role - NZO mouse 1389
- glutamine metabolism A66
- measurement in vivo 831
- Glucosamine - glucotoxicity, role in 518
- glycogen synthesis, effect on - skeletal muscle A133
- Glucose - 6-phosphatase - cDNA probe - rat A154
- - non-esterified fatty acids, inhibition by A144
- effectiveness - measurement in vivo A126
- - obesity A159
- fatty acid cycle 326
- glucose-6-phosphate cycling 337
- intestinal absorption - portal insulin, effect of - mechanism A135
- oxidation - stable isotope method A67
- production - gluconeogenesis, contribution of 831
- - hepatic - assessment A31
- - - labelled infusion 699
- - - diabetes - Type 1 337
- - - Type 2 326
- - - dimeric insulin analogue, effect of 1007
- - - Krebs cycle involvement 831
- - - NIDDM 3r
- - - New Zealand Obese mouse 1389
- - - non-esterified fatty acids, effect of A66
- - liver - insulin, effect of - dog A154
- - obesity A67
- - - fructose ingestion, effect of in NIDDM A151
- release [see Glucose - production]
- sensor [see also EASD - Study Group - AIDSPIT] A183-A184
- tolerance - impaired - epidemiology 306
- - - glucagon receptor gene not associated 1246
- - - heterogeneity A11
- - - insulin sensitivity 699
- - - islet function A12
- - - macrovascular disease and 86
- - - nerve function A235
- - - pathophysiology 3r
- - - pregnancy - subsequent glucose tolerance A284

- - - prognosis - insulin & proinsulin levels and A 166
- - - progression - insulin response 187
- - - cardiovascular risk factors and A 188
- - pregnancy A 283
- - test - IV *[see also* Glucose - production; Insulin - secretion/
- - - insulin sensitivity measurement A 126, A 127
- - - non-esterified fatty acid suppression 1358
- - - insulin response, specific 1239
- - - reactive hypoglycaemia assessment 494
- - Vitamin D and - London Asians 1239
- transport A 132-A 135
- adipocyte - tumour necrosis factor, effect of 764
- assessment - photolabelling 661
- insulin-secreting cell - troglitazone, effect of 24
- mesangial cell - rat 291
- muscle - hyperglycaemia, effect of A 10
- Na⁺-coupled 291
- transporter *[see* GLUT/
- turnover - GLP-1 (7-36 amide), effect of - pig A 168
- - - *Erratum EASD News Section 10/95* 47
- - measurement A 125
- - obesity - childhood 739
- - uptake - GLP-1, role of A 169
- - skeletal muscle - hypomagnesaemic rat 1262
- - non-esterified fatty acids, effect of A 67
- - splanchnic - OG clamp A 31
- Glucotoxicity *[see* Insulin - secretion/
- GLUT (Glucose transporter) A 132-A 135
- 1 - polymorphism - single-strand conformation 942
- 2 - gene - promoter - insulin-secreting cell 112
- - gene promoter - insulin-secreting cell A 68
- - islet B-cell - calorie restriction, effect of - *fa/fa* rat 173
- - polymorphism 211
- 4 - adipocyte - human vs rat 661
- - expression - lipoic acid, effect of A 9
- - skeletal muscle - GLP-1 (7-36 amide), effect of A 172
- - - oöphorectomy, effect of A 130
- - internalisation - insulin, effect of A 9
- - translocation A 10
- - adipocyte 1148
- - ubiquitin-conjugating enzyme association A 9
- downregulation by glucose - muscle A 10
- expression - islet B-cell - rat vs human A 10
- - nerve A 9
- Glutamic acid decarboxylase - 65kD - human recombinant 14
- gene - Type 1 diabetes A 42
- molecular mimicry: α 2-macroglobulin 874c
- Glutathione - diabetes, reduced in - oxidative stress and 201
- synthesis - γ -glutamylcysteine synthetase 201
- Glycaemic control - diagnosis of complications, effect of A 278
- diabetic nephropathy and 1007, A 208
- diabetic neuropathy and A 234, A 235
- glycogen synthase expression and 1230
- haemorrhological effect A 259
- intraperitoneal insulin infusion 577
- lipoprotein(a) and - Type 2 diabetes A 250
- mortality, effect on - NIDDM in elderly 672
- nerve function and - childhood IDDM 685
- Type 1 diabetes - childhood A 52
- VLDL subfractions, effect on? - Type 1 diabetes 1419
- Glycation *[see also* Aminoguanidine; HbA_{1c}] A 160-A 162
- advanced end-product - diabetic nephropathy, in 387
- - kidney and A 47
- albumin - matrix-assisted laser desorption ionisation 1069
- inhibitor - aminoguanidine *[see also* Aminoguanidine/ 1271
- - D-lysine 1271
- - endothelial cell, effect on 1271
- insulin & proinsulin A 92
- LDL 1300
- Glycerol - subcutaneous monitoring for hypoglycaemia A 201
- Glycogen - synthase - expression - sulphonylurea and 1230
- - gene - diabetes - Type 2 1249c
- - hypertension 1249c
- - long-chain acyl CoAs, effect of A 143
- - *Macaca mulatta* A 156
- - muscle - negative feedback control A 66
- - - regulation A 122
- - polymorphism - Type 2 diabetes A 74
- - regulation - protein phosphatase 1 β 461
- - skeletal muscle - blood pressure and A 164
- - - Type 2 diabetes 326
- synthesis - protein phosphatase-1 G-subunit polymorphism A 75
- - skeletal muscle - GLP-1 (7-36 amide), no effect of 864, A 168
- turnover - liver - glucagon, regulation by A 66
- Glycogenesis *[see* Glycogen - synthase; Glycogen - synthesis/
- Glycogenin - skeletal muscle - cDNA cloned A 76
- Glycogenolysis - regulation - AMP kinase-activated kinase A 143
- Glycolysis - insulin secretion, role in A 101, A 102, A 122
- Growth - factor - ciliary neurotrophic factor - nerve, effect on A 233
- - insulin-like *[see* IGF/
- - platelet-derived - diabetic retinopathy A 57
- - transforming - complications of diabetes and A 254
- - vascular endothelial - diabetic retinopathy A 57
- fetal - adult diabetic nephropathy not related A 222
- - adult insulin resistance and A 136
- - adult NIDDM and A 176
- - maternal glucose tolerance and A 283
- - skeletal muscle glycolysis in adult life and 1205
- hormone - binding protein - obesity, in A 131
- - hGH₄₄₋₁₉₁ - diabetogenic potency reduced in rat A 155
- - signal processing - insulin-secreting cell A 118
- - very low calorie diet, response to - obesity, lacking in A 160
- Guanine nucleotides - insulin secretion, role in A 103
- Gustatory sweating A 238

H

- Haemochromatosis - screening A 13
- Haemoglobin - fetal - diabetes A 184
- glycated *[see* HbA_{1c}/
- - Graz - HbA_{1c} assay by HPLC 122c
- Haemorrhology *[see also* Haemostasis/
- diabetes A 258-A 260
- nitrate, effect of - diabetes A 252
- Haemostasis - diabetes A 256-A 258
- diabetic nephropathy 73, A 214
- fibrinogen, plasma - cardiovascular risk factor 630c
- - NIDDM A 166
- - proinsulin-like molecules and 1110
- - microalbuminuria - Type 2 diabetes A 218
- HAL - Class II - antigen presentation - molecular structure 1251
- Hamster - Syrian golden - islet regeneration 906
- HbA_{1c}, HbA_{1c} - assay - HPLC - Hb Graz interference 122c
- - inter-laboratory comparison A 184
- Hearing - WBN/Kob rat, impairment in 649
- Heart - cardiomyopathy, diabetic - ACE inhibitor, effect of 509
- - stereology - streptozotocin-diabetic rat 413
- coronary angiography 726
- coronary disease A 266-A 267
- - diabetic autonomic neuropathy and A 243
- - glucose tolerance and A 20
- - impaired glucose tolerance, in 585
- - microalbuminuria and - NIDDM A 222, A 223
- - microvascular angina - insulin resistance in A 152
- - risk factors - diabetes and 487
- - screening - diabetes 726
- coronary vascular reactivity - diabetes - oxidative stress, role of 1157
- diabetic autonomic neuropathy - scintigraphy
- ECG - ambulatory monitoring 726
- - exercise test 726
- - QT_c - diabetes 1345
- - - diabetic autonomic neuropathy A 239
- - - hypoglycaemia, in A 18
- - ventricular extrasystole - insulin resistance and A 163
- echocardiography - diabetes A 266

Heat shock protein

- endothelial cell - rat 430
- exercise, response to - diabetes 244
- K^{+}_{ATP} channel - sulphonylurea, effect of 116r
- left ventricular function - diabetic autonomic neuropathy A266
- - Type 1 diabetes A20
- left ventricular mass - Na^{+}/Li^{+} countertransport and 454
- myocardial energy status - diabetic ketoacidosis, in 889
- myocardial glucagon, effect of A129
- myocardial infarction A267, A268
- - ACE polymorphism and 948
- - mortality in diabetes A20
- - sulphonylureas and 116r
- myocardial metabolism - adrenergic activation - diabetic dog A153
- myocardial perfusion - diabetes - ACE inhibitor, effect of 509
- rate variability - diabetic autonomic neuropathy A241
- scintigraphy - ^{123}I -MIBG 1345
- - ^{99m}Tc -methoxyisobutylisonitrile 1345
- - thallium 726
- sympathetic damage - NIDDM A20
- Heat shock protein - islet - cytokines, induction by A17
- - man vs rat A45
- synthesis - ageing and AGEs, effects of A160
- Helicobacter pylori* infection - diabetes A245, A246
- Heparan sulphate - glomerular - albuminuria and - diabetic rat 161
- - diabetic nephropathy 1455
- proteoglycan - polymorphism - albumin excretion rate and A229
- Heparin - kidney, effects on - streptozotocin-diabetic rat A207
- Hepatitis - B - vaccine - response in Type 1 diabetes A100
- C - glucose tolerance in - interferon- α therapy A13
- Hepatocyte - GLP-1 (7-36 amide), effect of A172
- Hexokinase - activity reduced in NIDDM - not genetic 1466
- gene - MODY not linked 1055
- - mutant A60
- - NIDDM A34
- - organisation 1466
- - Type 2 diabetes 1466
- polymorphism 617
- skeletal muscle - phosphorylation, role of A145
- Hirata's disease [see Insulin - autoimmune syndrome/]
- HLA - Class I - diabetes - Type 1 - Finland 750c-752c
- - P3 loci - Type 1 diabetes - age at onset 623
- Class II - diabetes - Type 1 - insulin gene interaction 1223
- - - Yakutia 749c
- - - Type 2 - age at onset 748c
- - - Chile 378c
- - DQ - molecular structure - Type 1 diabetes 1251
- - TAP2 - Type 1 diabetes 968
- diabetes - Type 1 - susceptibility vs heterogeneity 1493c
- DM - Type 1 diabetes not associated A73
- DQ - A1 - promoter polymorphism - Type 1 diabetes A28
- - B1 - retroviral long terminal repeats - Type 2 diabetes A35
- - prediction of Type 1 diabetes in families A42
- haplotype - Type 1 diabetes susceptibility A72
- HMG CoA reductase inhibitor - lovastatin - diabetic nephropathy 604
- pravastatin - erythrocyte, effect on A258
- HOMA (homeostatic model assessment) [see Insulin - secretion/]
- Hyaluronan 298
- Hypercholesterolaemia [see also Cholesterol; Dyslipidaemia; Lipoprotein/]
- diabetic nephropathy, role in 604
- Hyperglycaemia - postprandial in IDDM - glucagon, role of 337
- Hyperinsulinaemia - diabetic autonomic neuropathy, effect in A239
- blood pressure, effect on A225
- childhood - hypertriglyceridaemia, risk factor for 1042
- cognitive function and 1096
- gastrointestinal motility, effect on 79
- insulin resistance during - insulinoma cases A150
- Hyperproinsulinaemia - familial - genetics A76
- Hypertension A224-A226
- adverse lipid profile, with - childhood hyperinsulinaemia predicts 1042
- birth weight and A176
- diabetes, with - animal model A73
- - EASD Study Group EASD News Section 11/95 51
- - kidney and 254b
- essential - IVGTT findings A112
- genetics - glycogen synthase gene 1249c
- insulin resistance syndrome, in 839
- insulin sensitivity A163-A164
- Na^{+}/Li^{+} countertransport and - NIDDM 356
- nocturnal - diabetic nephropathy, in 216
- parental microalbuminuria and A222
- treatment [see also Angiotensin - converting enzyme; Calcium - channel/]
- - diabetes - bendrofluazide, low-dose 853
- - retina, effects on A58
- - retinopathy progression and A277
- Hyperthyroidism - protein metabolism in A23
- Hypertriglyceridaemia [see also Dyslipidaemia; Lipoprotein; Triglyceride/]
- cardiovascular risk factors and 1358
- insulin resistance, in 344
- prediction - hyperinsulinaemia in childhood 1042
- renal effects in IDDM A247
- risk factor for abnormal glucose tolerance A249
- Hypoglycaemia A200-A205
- cerebral blood flow, effect on 1090
- cognitive function during 1412
- counterregulation - impaired following hypoglycaemia 1183
- - stepped hypoglycaemic clamping 1412
- exercise-induced in IDDM A179
- - fast insulin analogue, use of 106
- insulin resistance following - lipolysis and A18
- physiological response to - previous hypoglycaemia and A18
- pregnancy - Type 1 diabetes A282
- reactive - assessment - standard meal 494
- unawareness - hypoglycaemia-induced 1183
- - intensive insulin therapy, during 1412
- - Type 2 diabetes A19
- Hypoglycaemic agent A193-A200
- 4-hydroxyisoleucine A101
- A4166 A194, A196
- BPDZ 62 A195
- BRLP-42 - diabetic neuropathy, prevention of - rat A233
- herbal - fenugreek A101
- - *Gymnema sylvestre* A193
- - *Lupinus albus* A109
- - *Momordica charantia* A193
- meglitinides A194, A199
- molybdate A138, A193
- oral - secondary failure - insulin secretion A198
- pregnancy, use in - glyburide? 753
- repaglinide 1025, A43, A194, A195
- selenium compounds A133
- sulphonylurea [see Sulphonylurea/]
- thiazolidinediones A199, A200
- - darglitazone 1307
- - troglitazone 24, A199, A44
- thioctic acid A199
- troglitazone [see Hypoglycaemic agent - thiazolidinediones/]
- vanadate - adipocyte, effect on A141
- - insulin secretion - inhibition of in normal rat A103
- - intestine, effect on 403
- - skeletal muscle effects - tungsten compared A143

I

- IAPP [see Amylin/]
- IDDM (Insulin-dependent diabetes mellitus) [see Diabetes - Type 1/]
- IGF (Insulin-like growth factor)
- binding protein - 1 - postprandial responses A152
- - 2 - bladder hypertrophy and - diabetic rat A64
- - retinal endothelial cell A275
- I - bone fibroblast, effect on A125
- - expression - liver - human vs rat A154
- - insulin secretion, regulation of A111
- - nerve, effect on A8
- - NIDDM, in A132
- - receptor - expression - liver - human vs rat A154
- - therapy - IDDM A44
- - vascular smooth muscle, effect on A53
- II - expression - insulin-secreting cell 927
- - tumour-induced hypoglycaemia, in A204
- mesangial cell, effect on A64

- IGT *[see* Glucose – tolerance – impaired/
Immunotherapy *[see* Diabetes – Type 1 –
disease-modifying therapy/
Impotence *[see* Erectile failure/
Incretin *[see also* GLP] – GLP-1 (7–36
amide) 720
Infra-red spectrometry – glucose sensor
A 183
Inheritance of diabetes – Type 1 – age at
onset A 73
– sex of affected parent, effect of 715,
A 73
– Type 2 – maternal *[see also* Gene – mito-
chondrial; MIDD] 14, 314, 1482c
Insect cell transfection – human GAD65
Instructions for Authors *Advertisement*
pages, Jan & July issues
Insulin – analogue A 189–A 192
– covalent dimers 1007
– hepatoselective 1007
– monomeric – B10Asp 592
– lispro (Lys(B28),Pro(B29)) A 3,
A 4, A 189–A 191
– exercise hypoglycaemia 106
– slow-acting A 191, A 192
– HOE901 A 4
– NN-304 A 4
– W99-S32 A 4
– antibody *[see* Insulin – autoantibodies;
Insulin – immunogenicity/
– assay – intact A 157
– autoantibodies – cord blood A 90
– islet-cell – B-lymphocyte subsets, re-
lease by 62
– autoimmune syndrome A 91
– degradation – brain – insulin species 757
– gene – diabetes – Type 1 1223
– expression – regulation – amylin ex-
pression compared 395
– mutant – familial hyperproinsulinae-
mia A 76
– promoter – TAAT motif function A 65
– RFLP – Type 1 diabetes A 28
– glycation A 161
– immunogenicity – human A 191
– intraperitoneal 577
– lispro insulin A 4
– infusion – device – implantable 577
– intraperitoneal 577
– intranasal 680
– intrapulmonary A 3
– like growth factor *[see* IGF/
– lispro *[see* Insulin – analogue – mono-
meric – lispro/
– oral – nanoencapsulated 180
– pancreatic acinar cells, binding to 262
– precursors – postprandial secretion A 113
– preparation – isophane – protamine, ad-
verse effect of A 254
– promoter factor 1 – islet regeneration
and A 45
– receptor – A-cell, pancreatic 422
– binding affinity – insulin resistance
and A 139
– brain – insulin binding – species, effect
of 757
– human – Chinese hamster ovary cells,
transfected 180
– species specificity 757
– internalisation – Cys 860, role of A 64
– processing – NIDDM A 129
– isoforms – radioimmunoassay 445
– mutant – insulin resistance – Type A
A 132
– Met985 – Type 2 diabetes A 77
– placental isoforms – gestational dia-
betes A 65
– signal transduction A 68, A 69
– islet transplantation, recovery after
A 86
– signalling A 122–A 125
– p21^{ras} A 116
– skeletal muscle – hypomagnesaemic
rat, in 1262
– Otsuka Long-Evans Tokushima Fat-
ty Rat 1033
– substrate-1 – adipocyte 1148
– gene – polymorphism 211, 481,
A 33, A 74
– promoter A 33
– tyrosine kinase – insulin resistance, in
55
– magnesium, role of 1262
– muscle PC1 content and A 34
– NIDDM A 33
– release *[see* Insulin – secretion/
– resistance *[see also* Insulin – sensitivity/
3r, A 33, A 136–A 141
– abdominal obesity and A 188
– African Americans – resident vs re-
cently immigrant 1103
– antibody-mediated – human insulin
A 191
– chronic renal failure 565
– darglitazone, effect of 1307,
diabetes – Type 2 1378r, 992r
– hexokinase 1466
– hexokinase II polymorphism and 617
– hypertension in – amylin role? A 131
– Na⁺/K⁺ ATPase inhibitor role? 792
– hypomagnesaemia, in 1262
– impaired glucose tolerance, in 187
– insulin receptor tyrosine kinase activ-
ity 55
– insulin-induced – adipocyte 1148
– L-arginine, effect of – obesity A 158
– macrovascular disease risk – oxidative
stress, role of 1484c
– microalbuminuria and A 221–A 224
– obesity – animal models 998r
– Otsuka Long-Evans Tokushima Fatty
Rat 1033
– ouabain-like immunoreactivity 792
– PC-1 glycoprotein, role of A 65
– protein phosphatase 1 β gene not
linked 461
– streptozotocin-diabetic rat 283
– syndrome A 163–A 166
– dyslipidaemia in – lipase ratio 344
– genetics A 79
– hypertension, role of 839
– LDL size in 1328
– Lewis phenotype and A 78
– thiazide, effect of – low-dose 853
– treatment – troglitazone A 44
– tumour necrosis factor, role of 764
– Type A – insulin receptor mutation
A 132
– phosphatidylinositol 3'-kinase acti-
vation impaired A 137
– sc injection – computer-assisted A 186
– secreting cell – BRIN-BG7 A 108
– glucose sensitivity – different cell lines
A 108
– human insulinoma line A 46
– human proinsulin-transfected A 84
– IGF-II expression – glucose, effect of
927
– secretory granule – sulphonylurea re-
ceptor 277
– sulphonylurea receptor 277
– transgenic pituitary A 55
– secretion A 15
– assessment in vivo A 30
– Ca²⁺-stimulated – permeabilised GK
rat islet 772
– diabetes – Type 2 3r, 986r, 992r
– exocytosis 772
– syntaxin role? 860
– fetus 124c
– GK rat – permeabilised islets 772
– GLP-1 (7–36 amide), effect of 720,
A 39
– Zucker rat A 171
– glucagon-stimulated – glucagon recep-
tor involved 274
– glucose-stimulated – signal transduc-
tion 779
– glucotoxicity A 110, A 46
– aminoguanidine, effect of A 93
– glucosamine, role in 518
– pyruvate dehydrogenase, role of
A 96
– imidazole compounds, stimulation
by A 95
– impaired glucose tolerance 699
– interleukin-1 β , effect of 779
– copper, effect of 39
– measurement in vivo A 126
– modulation mechanisms 1276
– neurotransmitters, effect of – strepto-
zotocin-diabetic rat 1276
– non-esterified fatty acids, effect of –
long vs short-term 1285
– NSY mouse 503
– obesity – animal models 998r
– phospholipase A₂ activation, role of
A 93
– signal transduction A 115–A 125
– studies *in vitro* A 101–A 111
– studies *in vivo* A 111–A 115
– troglitazone, effect of 24
– sensitivity *[see also* Insulin – resistance/
– GLP-1 (7–36 amide), no acute effect
of A 168
– glucotoxicity 518
– impaired glucose tolerance 699
– insulin delivery route and A 125
– measurement – *in vivo* A 125–A 127
– serum – diabetes – Type 1 – age, effect of
97
– species – human insulin activity in rat?
1492c
– insulin receptor binding 757
– non-human – availability 1492c
– insulin resistance syndrome 1328
– specific – serum – cardiovascular risk fac-
tors and 1110
– therapy – exercise A 179
– NIDDM A 136
– treatment – intensive *[see also* EASD –
Study Group – AIDSPIT/
– diabetic nephropathy A 208
– haemorrhological effect A 259
– hypoglycaemia, avoiding A 18
– islet B-cell function, effect on A 51

Insulinoma

- - - long-term A 51
- - Type 2 diabetes A 25
- Insulinoma - genetic abnormalities A 77
- IVGTT findings A 112
- Insulinitis [see also Lymphocyte]
- protein expression during - BB rat vs allograft rejection A 85
- subtotal pancreatectomy, induced by 1397
- Interleukin - 1 - receptor - gene - Type 1 diabetes A 72
- 1 β - insulin secretion, effect on 779
- - insulin-secreting cells or islets, effect on A 82
- - - protection against A 80, A 81
- - - copper, protection by 39
- - - NOD mouse 153
- - - pure insulin-secreting cells and islets compared A 117
- - - rat strain dependence A 17
- Intestine - GLP-1 secretion A 170, A 171
- glucose transport - vanadate, effect of - diabetic rat 403
- Ion flux - islet B-cell [see B-cell, islet - Ca²⁺; B-cell, islet - K⁺]
- Islet - acinar portal system 262
- amyloid polypeptide [see Amylin]
- B-cell [see B-cell, islet; Insulin - secreting cell; Insulin - secretion]
- Ca²⁺ - oscillation - culture factors affecting 876c
- culture - Ca²⁺ oscillation, effect on 876c
- FAD-glycerophosphate dehydrogenase - ontogeny A 27
- glucose metabolism - interleukin 1 β , effect of 39
- Kearns-Sayre syndrome, in 868
- mRNA - in-situ hybridisation 395
- nitric oxide, effect of A 17
- NSY mouse 503
- permeabilised - insulin secretion - GK rat 772
- reg gene expression 906
- regeneration - animal model - cellophane-wrapped pancreas 906
- - insulin promoter factor A 45

K

- K⁺_{ATP} channel - islet B-cell [see also B-cell, islet] 1025
- Kearns-Sayre syndrome - islet function 868
- Ketoacidosis, diabetic - alkali infusion, effect of 889
- gastroparesis in - fatty acids, role of 632c
- magnetic resonance spectrometry - ³¹P 889
- starved streptozotocin-diabetic rat 889
- vasodilatation in - prostaglandins, role of A 261
- Kidney - diabetes - Albert Renold Fellowship 1995 *EASD News Section 10/95* 43
- - hypertension and 254b
- loop of Henle - Tamm-Horsfall glycoprotein 525
- single - microalbuminuria and - NIDDM A 216
- Tamm-Horsfall glycoprotein - streptozotocin-diabetic rat 525

L

- Lactate - infusion - glucose utilisation, effect on A 12
- - hypoglycaemia, during A 203
- serum - exercise, effect of - diabetic rat 919
- - postprandial rise - amylin, role of A 155
- Lactic acidosis - diabetic ketoacidosis - alkali infusion effect 889
- Laminin - P1 - diabetic retinopathy A 57
- serum - panretinal photocoagulation, effect of A 275
- Laser Doppler flow measurement 129, 467, 555, 1337
- Lens - glucose phosphorylation A 145
- Leucocyte - motility A 259, A 260
- Levosulpiride - gastroparesis treatment - hypoglycaemic effect A 245
- Limited joint mobility - Type 1 diabetes - complications A 187
- Lipase [see also Lipolysis] - hepatic - diabetes - Type 1 1419
- Lipid-lowering agent [see also HMG CoA reductase inhibitor]
- benfluorex - NIDDM, use in A 197
- diabetic nephropathy progression, effect on 604
- Lipids [see also Apolipoprotein; Cholesterol; Dyslipidaemia; Hypercholesterolaemia; Hypertriglyceridaemia; Lipoprotein; Triglyceride]
- serum - NIDDM A 247-A 250
- obesity - childhood 739
- Lipoatrophic diabetes - liver transplantation, effect of A 140
- Lipoatrophy - insulin-induced - TNF- α , role of A 187
- Lipodystrophy - abdominal obesity, with - metabolic studies A 156
- Lipoic acid [see Thioctic acid]
- Lipolysis - diabetes - Type 1 1419
- diurnal rhythm - Type 1 diabetes A 151
- enzyme profile - insulin resistance syndrome, in 344
- gestational diabetes, in A 280
- hypertension, in A 163
- inhibitor - GR 79236 - gastric motility in DKA, effect on 632c
- insulin, effect of - glycerol clamp method A 149
- subcutaneous glycerol release - obesity A 159
- Lipoprotein [see also Apolipoprotein; Cholesterol; Dyslipidaemia; Hypercholesterolaemia; Hypertriglyceridaemia; Triglyceride]
- (a) - diabetes A 250, A 251
- - glycaemic control and - Type 1 diabetes A 26
- - macrovascular disease and - diabetes 711
- - serum - families of Type 2 diabetic patients 1434
- HDL - serum - LDL subclasses and 1328
- HMG CoA reductase inhibitor, effect of - diabetic nephropathy 604
- insulin resistance syndrome 344
- LDL - apolipoprotein (a) binding [see Lipoprotein - (a)]

- - composition - diabetes, in 1300
- - - serum triglycerides, effect of A 249
- - glycaemic control and - Type 1 diabetes A 26
- - glycation 1300, A 26
- - hexose release, effect on A 162
- - insulinaemia and A 248
- - oxidation - diabetes, increased in 1300
- - - fatty-acid composition and 1300
- - serum - proinsulin-like molecules and 1110
- - sialic acid concentration - diabetic nephropathy A 247
- - size - insulin resistance syndrome, in 1328
- - subclasses 1328
- peroxidation - magnesium and A 246
- serum - adverse profile predicted by childhood hyperinsulinaemia 1042
- - albumin excretion rate and - Type 2 diabetes A 215
- - exercise, effect of - NIDDM 1313
- Type 2 diabetes - insulin, effects of A 248
- VLDL - apolipoprotein B turnover - insulin action A 247
- - apolipoprotein B-100 959
- - subfractions - IDDM 1419
- Liver - insulin resistance and A 153
- Lundbaek, Knud - obituary *EASD News Section 9/95*, 35
- Lupus anticoagulant [see Antibody - phospholipid]
- Lymphocyte - activated - detection in islets *in vivo* A 38
- antioxidant activity - Type 1 diabetes A 252
- B - EBV-transformed 62
- CD23 expression - Type 1 diabetes A 80
- - subsets - auto-antibody production in Type 1 diabetes 62
- CD95 expression - Type 1 diabetes 1449
- subpopulations - pregnancy A 70
- T - adoptive transfer of diabetes - BB rat 145
- - bcl-2 expression - Type 1 diabetes 953
- - CD95 - Type 1 diabetes, expression reduced in A 37
- - CDR3 sequence - Type 1 diabetes A 38
- - GAD reactivity - Type 1 diabetes A 38
- - insulin-specific - Type 1 diabetes A 80
- - insulinitis, role in following subtotal pancreatectomy 1397
- Lysine [see Glycation - inhibitor]
- Lysosome - alloxan toxicity, role in 635
- enzyme - α -glucosidase - insulin secretion, role in A 108

M

- Macaca mulatta* (rhesus monkey) - glycogen synthase A 156
- Macrophage - lipoprotein (a), effect of A 251
- Macrovascular disease A 19, A 52, A 266-A 270
- angiotensin converting enzyme polymorphism and A 227, A 228
- angiotensin-II receptor polymorphism A 228, A 229
- glucose tolerance and - Hoorn study 86

- impaired glucose tolerance, in 585
- insulin resistance, in - oxidative stress, role of 1484c
- stroke *[see Stroke]*
- ultrasonography 585
- WHO MONICA project 1061
- Magnesium - deficiency - insulin receptor tyrosine kinase effect 1262
- hypertension, in A 226
- lipid peroxidation and A 246
- metabolism - Type 1 diabetes A 150
- NIDDM, in A 226
- serum - albumin excretion rate and - IDDM 629c
- Magnetic - resonance - imaging - nerve - diabetic neuropathy A 231
- - - spectrometry, ³¹P - diabetic ketoacidosis 889
- - - muscle glycolysis 1205
- stimulation - central motor pathways 1191
- Major histocompatibility complex *[see HLA; MHC]*
- Malaria - hypoglycaemia - animal model A 200
- Malnutrition-related diabetes mellitus - ketosis resistance A 13
- MAP *[see Mitogen-activated protein/]*
- Mass spectrometry - islet ganglioside 1117
- protein - matrix-assisted laser desorption ionisation 1069
- Maternally-inherited diabetes with deafness 193, A 75, A 78
- macular retinal dystrophy in A 77
- MELAS, relationship with 1487c
- treatment - coenzyme Q10 & L-carnitine? 1484c
- Mathematical model - glucose tolerance tests A 125-A 128
- Maturity-onset diabetes in youth *[see MODY]*
- Meal - standard mixed - reactive hypoglycaemia assessment 494
- MELAS (Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) *[see also Kearns-Sayre syndrome/]*
- cerebral perfusion 1004c
- features in NIDDM in Japan 193
- mitochondrial mutation 1487c
- Mesangial cell *[see Glomerular/]*
- Metformin A 197, A 198
- UK Prospective Diabetes Study A 24
- Methyl pyruvate - insulin secretion, effect on A 102
- Mevalonic acid - gas chromatography mass spectrometry 959
- MHC (major histocompatibility complex) *[see also HLA/]*
- Class I - islet B-cell expression - BB rat 1138
- glucose transport, role in A 133
- MIBG (metaiodobenzoylguanidine) - ¹²³I *[see Scintigraphy/]* 1345
- Microalbuminuria A 210-A 212
- carotid artery disease and A 269
- diabetes, Type 2 356
- - - monounsaturated fat diet, effects of 1069
- - - vascular mortality and 610
- glomerular epithelial foot processes in - diabetes 1197
- hyperproreninaemia preceding - IDDM A 62
- hypomagnesaemia and - IDDM 629c
- insulin resistance and A 221-A 224
- - - relatives of NIDDM subjects 363
- juxtaglomerular arterioles - IDDM 1320
- LDL sialic acid concentration and A 247
- NIDDM, in - fibroblast glucose uptake & Ca²⁺ A 141
- - - lipoprotein (a) and A 251
- progression - risk factors A 215, A 216
- - - Type 2 diabetes A 63
- risk factors for - Type 2 diabetes A 63
- vascular autoregulation A 263
- Microdialysis - se glucose sensing A 183
- Minkowski - Lecture 1993 - insulin resistance in NIDDM 1378r
- Prize & Lecture 1995 - John Todd *EASD News Section 10/95 39*
- Mitochondrial, mitochondrion *[see also Gene - mitochondrial/]*
- ATP production - bioluminometric method - islet B-cell A 144
- metabolism *[see also Pyruvate - dehydrogenase/]*
- - - embryopathy and - diabetic pregnancy A 21
- myocardial - streptozotocin-diabetic rat 413
- - - myopathy, encephalopathy, lactic acidosis and stroke *[see MELAS/]*
- respiration - polarography - islet B-cell A 95
- Mitogen-activated protein kinase - adipocyte 1148
- - - glycogen synthesis, role in A 125
- MODY (Maturity-onset diabetes in youth) - family study A 34, A 60
- - - chromosome 12 A 74
- - - linkage studies 1055
- prevalence - central Europe 1482c
- Molecular mimicry - GAD and α 2-macroglobulin 874c
- MONICA (Multinational Monitoring of Trends and Determinants in Cardiovasc. Dis.) 1061
- Monkey - rhesus *[see Macaca mulatta/]*
- Morphometry - glomerulus - basement membrane 1169
- - - SHR/N-cp rat 31
- - - islet - NSY mouse 503
- Mortality - cardiovascular - diabetes - Type 2 610
- - - body mass index, effect of A 59
- - - Italy 318
- - - stroke 1061
- - - Type 2 - glycaemic control and 672
- - - microalbuminuria and 610
- diabetic nephropathy - Japan vs Pennsylvania, USA 236
- - - Pima Indians A 63
- - - smoking, effect of A 209
- diabetic retinopathy A 278
- stroke, diabetes and 1061
- Mouse - *db/db* - fatty acids and islet B-cell function A 93
- New Zealand Obese - Type 2 diabetes model 1389
- NOD - islet B-cell injury - interleukin 1 β vs nitric oxide 153
- - - nicotinamide treatment A 97
- - - *reg* gene expression A 74
- NSY (Nagoya-Shibata-Yasuda) - Type 2 diabetes model 503
- nude - human islet transplant - amyloid 543
- transgenic - aldose reductase 255
- - - glucocorticoid receptor overexpressing, islet B-cell A 128
- - - GLUT-4 overexpressing A 11, A 15
- - - preproinsulin-expressing pituitary cell A 55
- - - superoxide dismutase - embryopathy, diabetic A 21
- Muscle - skeletal *[see also Glucose - transport; GLUT/]*
- - - ³¹P magnetic resonance spectroscopy 1205
- - - blood flow - insulin, effect of 555, A 50
- - - diabetes, Type 2 3r
- - - eccentric exercise - insulin sensitivity, effect on A 179
- - - GLP-1 (7-36 amide), effect of A 39
- - - glucose metabolism - Type 2 diabetes 326
- - - glucose transport - NIDDM A 151
- - - glucose uptake - blood flow, effect of A 50
- - - glutamine:fructose-6-phosphate amidotransferase A 152
- - - glycogen synthase - sulphonylurea therapy 1230
- - - glycogenesis - GLP-1 (7-36 amide), no effect of 864
- - - glycogenolysis - insulin resistance, delayed in A 67
- - - glycolysis - low birth-weight adults, in 1205
- - - insulin, effect of - training & ageing effects A 11
- - - insulin receptor tyrosine kinase activity 55
- - - insulin resistance - Otsuka Long-Evans Tokushima Fatty Rat 1033
- - - interstitial insulin concentration A 153
- - - oxygenation - Type 1 diabetes A 253
- - - phosphotyrosine phosphatase - hyperinsulinaemia, effect of A 11
- - - plasma membrane - exercise & ageing, effects of A 179
- - - sensory denervation - insulin sensitivity following A 138
- - - smooth - growth - insulin, effect of - streptozotocin-diabetic rat A 147
- - - vascular *[see also Vascular - reactivity/]*
- - - - - cyclic nucleotides in 936
- - - - - proliferation A 53
- Myo-inositol - therapy - renal effects - diabetic rat 899
- Myocardial infarction *[see Heart - myocardial infarction/]*

N

- Nephropathy - diabetic A 62, A 208-A 214
- - - angiotensin converting enzyme inhibition A 218-A 221
- - - biochemical mechanisms - rat 387
- - - collagen expression 632c
- - - EASD Study Group *EASD News Section 9/95, 35 w*
- - - glomerular basement membrane 1455

Nerve

- - glomerular epithelial foot processes 1197
- - glycaemic control and - islet transplantation in rat 1007
- - hyperfiltration - streptozotocin-diabetic rat 536
- - juxtaglomerular arterioles in 1320
- - NIDDM A215-A218
- - nocturnal hypertension 216
- - octreotide, effect of - rat 135
- - pregnancy in 227
- - procoagulant activity in 73
- - prognosis A46
- - progression - ACE inhibitor - beta-blocker as good? 123c
- - lipid-lowering therapy, effect of 604
- - myo-inositol therapy, effect of 899
- - SHR/N-cp rat 31
- - susceptibility - diabetic retinopathy and 599
- experimental studies A206-A208
- galactose-fed rat - polyol pathway 46
- Nerve - acetyl carnitine, effect of - diabetic rat 872c, A7, A8
- - cilostazol, effect of - streptozotocin-diabetic rat 914
- - laser Doppler 129
- - streptozotocin-diabetic rat 1285
- conduction study - reproducibility A235
- diabetes - anti-oxidant treatment 129
- function - diabetes - childhood 685
- IGF-I, effect of A8
- Na⁺/K⁺ ATPase - cilostazol, effect of - diabetic rat 914
- reductive stress - diabetic rat A8
- regeneration in diabetic neuropathy - aldehyde reductase inhibitor A233
- Nesidioblastosis, neonatal A15
- Neuropathy - autonomic diabetic A237-A241
- - ¹²³I-MIBG scintigraphy - heart 1345
- - cardiac A241-A243
- - diurnal variation in BP & AER A213
- - exercise, response to 244, 1003c
- - gastroparesis A32
- - hypoglycaemia response A203
- - diabetic - anti-oxidant treatment 129
- - central motor pathways in 1191
- - childhood - glycaemic control 685
- - cilostazol therapy 914
- - clinical studies A235-A238
- - experimental studies A230-A234
- - haemorrhological factors 872c
- - motor evoked potentials A7
- - oxidative stress, role of - streptozotocin-diabetic rat 1285
- - painful - spinal cord stimulator A7
- - peripheral vascular disease, role of 1051
- - pregnancy, in A285
- - treatment - lipoic acid 1425
- - visual evoked potentials 573
- Neuropeptide Y - intracerebral - hyperphagia 998r
- islet - glucocorticoid, expression induced by A147
- Neurotrophin - 3 - insulin-secreting cell, effect on A106
- Neutrophil, polymorphonuclear - oxidant production in NIDDM A252

- Nicotinamide /see Diabetes - Type 1 - disease-modifying therapy; Transplantation - islet/
- NIDDM (Non-insulin-dependent diabetes mellitus) /see Diabetes - Type 2/
- Nifedipine /see Calcium - channel - blocking agent/
- Nitric oxide - endothelium-dependent - diabetes A265
- - glucose, effect of A48
- - L-arginine, effect of in Type 1 diabetes A48
- insulin secretion, role in A109
- islet, effect on - DNA damage A17
- synthase - insulin-secreting cell A82
- NOD mouse islet 153
- NSY mouse /see Mouse/
- Nutrition /see also Diet/

O

- Obesity /see also Fat - distribution; Insulin - resistance - syndrome/ A158-A160, A164
- abdominal - exercise, effect of in NIDDM 1313
- - hypertriglyceridaemia and 1358
- animal model 998r
- childhood - glucose turnover 739
- fat distribution A58
- glucose turnover - childhood 739
- hyperinsulinaemia - β -endorphin, role of A112
- metabolism in A58, A59
- Obituary - Knud Lundbaek *EASD News Section 9/95*, 35
- Octreotide - diabetic nephropathy, effect on - rat 135
- kidney, effect on A206
- Oculomotor function - diabetes A236
- Oestrogen - replacement - NIDDM A25
- Okadaic acid /see also Phosphorylation - serine-threonine/
- insulin secretion, inhibition of A118
- Olive oil /see Diet - fat - monounsaturated/
- Oscillation - insulin secretion - assessment *in vivo* A127
- - basal A104
- - cAMP, effect of A104
- - insulin resistance and A148
- - phosphofructokinase, role of A16
- islet B-cell - cytosolic Ca²⁺ A121
- - - ATP/ADP ratio A109
- - - tetraethylammonium, effect of A94
- - K⁺ channels A123
- Osteonectin - expression - renal hypertrophy, reduced in A62
- Ouabain-like immunoreactivity 792
- Oxidation - LDL 1300
- Oxidative stress - alloxan-induced - insulin-secreting cell 635
- coronary vascular reactivity, effect on 1157
- diabetes A40, A252, A253
- diabetic embryopathy, role in A21, A281
- diabetic microangiopathy, role in - streptozotocin-diabetic rat 1285
- diabetic nephropathy, role in - rat 387
- diabetic neuropathy, role in - streptozotocin-diabetic rat 1285

- endothelial cell mitochondrial gene deletion induction A261
- insulin-secreting cell injury A253
- macrovascular disease, role in - insulin resistance and 1484c
- nerve, effect on A232
- retina - diabetes A276
- scavenging - diabetes, reduced in 201
- Oxaldehyde DH - 3-deoxyglucose scavenging, role in? A161
- Oxotremorine-M - islet B-cell, effect on A118

P

- PACAP (Pituitary adenylate cyclase activating peptide)
- receptor - gene - MODY and 1055
- insulin secretion, stimulation of - intracellular signalling A125
- Pancreas - biopsy - Type 1 diabetes - viral DNA studies 667
- duct cell - differentiation to islet B-cell 1405
- exocrine - islet hormones, effect of 262
- neural activity - conscious dog A155
- venous diversion - insulin sensitivity, effect on A137
- Pancreatectomy - subtotal - islet autoimmunity induction 1397
- Pancreatic polypeptide - diabetic autoimmune neuropathy, in A32
- Pancreatitis - tropical calcific - glucose homeostasis A139
- Perlecan gene A229
- pH - intracellular - islet B-cell A119
- Phosphatidylinositol 3'-kinase - hypertensive hypertriglyceridaemic rat A137
- inhibitor - wortmannin 1148
- Phosphodiesterase inhibitor - cilostazol - diabetic nerve, effects on 914
- Phosphofructokinase - insulin secretion, role in A16
- intestine - vanadate, effect of 403
- Phospholipase C - activation - GTP, role of in islets A117
- Phospholipid - fatty acid composition - NIDDM A139
- Phosphorylation - serine-threonine - insulin action, in - adipocyte A122
- Phosphotyrosine phosphate /see Muscle/
- Photolabel - glucose transport - ATB-BMPA 661
- Pima Indians - risk factors for NIDDM 187
- Pituitary - adenylate cyclase activating peptide /see PACAP/
- Placenta - diabetes A280, A281
- Plasminogen /see Fibrinolysis; Haemostasis/
- activator - inhibitor - hyperinsulinaemia, effect of - Pima Indians A139
- Platelet - leucocyte co-aggregation - diabetic neuropathy, role in A230
- membrane antigens - diabetes A162
- Polymorphism - HLA-DM A73
- insulin receptor substrate-1 gene 481
- RAD1 - Type 2 diabetes not associated A75
- TAP2 A72
- Polyol pathway - kidney - galactose-fed rat 46

- Portal hypertension – glucagon and insulin levels in A129
- Prediabetes – Type 1 – CMV infection 705
- GAD antibody A43
 - in utero? A90
 - insulin therapy [see also Diabetes – Type 1 – disease-modifying therapy] A99
 - insulinitis detection *in vivo* A38
 - islet-cell antibodies – 37kD 370
 - islet-cell associated autoimmunity A88
 - markers A42
 - Type 2 – non-esterified fatty acids, serum 1213
 - proinsulin & specific insulin, serum 1176
- Prediction – BB rat diabetes – soluble L-sectin A81
- hypertension – childhood hyperinsulinaemia 1042
 - insulin requirement in Type 2 diabetes A25
 - families A6
 - general population A54
 - islet-cell antibodies – 37kD 370
 - strategy 816
 - islet-cell associated autoimmunity A89
 - Type 2 diabetes A187, A188, A60, A61
 - non-esterified fatty acids 1213
- Pregnancy A280
- Coxsackie B infection – Type 1 diabetes risk in child 1371
 - diabetes A36
 - embryopathy – White class and A21
 - immunology A70
 - nephropathy, effect of 227
 - oral hypoglycaemic agent – glyburide? 753
 - normal – glucose tolerance A71
 - HbA_{1c} – pregnancy outcome and A36
 - insulin-like molecules – outcome and A37
 - islet blood flow – rat A94
 - protein malnutrition during – insulin resistance in offspring – rat A142
 - protein malnutrition, following – fetal glucose utilisation A36
- President, message from *EASD News Section 1/95*
- Programmed cell death [see Apoptosis]
- Proinsulin – assay – enzyme amplification A156
- conversion – assessment *in vivo* A114
 - NIDDM A114
 - convertase – PC₂ – sorting to granules A105
 - insulin ratio 1176
 - LDL subclasses and 1328
 - like molecules – serum cardiovascular risk factors and 1110
 - serum – prediabetes – Type 2 1176
 - split – vitamin D deficiency and 1239
 - Type 2 diabetes, levels in – treatment mode and A136
- Prolactin – signal processing – insulin-secreting cell A118
- Prostaglandin E₂ – glomerular hyaluronan production, effect on 298
- mesangial cell, effect on A207
- Protamine – vascular proliferation stimulated by A254
- Protein – body – diabetes, loss in – islet transplantation, effect of 881
- G [see G protein]
 - heat shock [see Heat shock protein]
 - kinase – C – activator – PMA – rat adipocyte, effect on A141
 - inhibitor – insulin secretion, effect on A16
 - insulin action, role in A122
 - insulin secretion, role in A123
 - isoforms – endothelial cell A255
 - II – calcium/calmodulin dependent – insulin-secreting cell A120
 - metabolism – regulation A22, A23
 - molecular weight – matrix-assisted laser desorption ionisation 1069
 - phosphatase – 1 – β – gene – insulin resistance not linked 461
 - Tamm-Horsfall – streptozotocin-diabetic rat kidney 525
- Psychology – well-being [see also Quality of life] – diabetes and A180–A182, A186
- Psychosocial aspects of diabetes – EASD study group *EASD News Section 7/95*
- Puberty – glucose homeostasis A113
- Publication redundancy and standards *Editorial* 1375
- Pulsatility [see Oscillation]
- Pyruvate – dehydrogenase [see also Insulin secretion]
- E1 catalytic subunit – phosphorylation monitoring A144
 - impaired glucose tolerance, marker of A33
 - kinase – islet 125c
 - carboxylase – hepatic – diabetic NZO mouse 1389
- ## Q
- Quality of life – diabetes and A180–A182
- ## R
- Radiographic contrast medium – renal function, effect on in DM A213
- Rat – BB – blood pressure A226
- diabetes – adoptive transfer 145
 - gastric emptying – amylin, effect of 642
 - genetics A73
 - immunotherapy A98
 - non-specific immune stimulation 145
 - prevention 1138
 - diet, effect of – islet B-cell MHC Class I expression 1138
 - MHC expression, islet A82
 - spontaneously hypertensive rat, hybrid with A79
 - Cohen diabetic – myo-inositol feeding 899
 - Dahl salt-sensitive – nephropathy A208
 - galactosaemic – cataract A276
 - galactose-fed – aldose reductase expression in kidney 46
 - GK Wistar – insulin secretion – L-leucine, effect of A103
 - Goto-Kazikaki (GK)
 - ageing A137
 - genetics A79
 - glucose-6-phosphatase activity, islet A143
 - insulin secretion 772, A146
 - hereditary hypertriglyceridaemic – genetics A225
 - ω -3 fatty acid, effect of A146
 - insulin sensitivity – insulin species 1492c
 - OLETF – sex hormones, effect of A147
 - Otsuka Long-Evans Tokushima Fatty – Type 2 diabetes model 1033
 - sand – cataract A276
 - SHR/N-cp [see Rat – spontaneously hypertensive – NIH-corpulent]
 - spontaneously hypertensive – ACE inhibitor, effect on A140
 - BB rat, hybrid with A79
 - NIH-corpulent – Type 2 diabetes model 31
 - streptozotocin-diabetic – body composition 881
 - diabetic nephropathy 387
 - glomerular basement membrane 1169
 - glucose production increased 283
 - glucose turnover A154
 - insulin sensitivity 283
 - nicotinamide-protected A103
 - ventromedial hypothalamic lesion – obesity model 998r
 - WBN/Kob – diabetic – hearing impairment associated 649
 - Zucker – *fa/fa* – diet, effect of on islet B-cell GLUT2 173
 - metabolic studies 998r
 - insulin resistance A138
- Reductive stress – retina – diabetes A276
- Renal – artery stenosis A268
- biopsy – diabetic nephropathy A217
 - Type 1 diabetes – glomerular volume A210
 - disease, non-diabetic – diabetes, in A217
 - mitochondrial gene mutation A229
 - failure – chronic – insulin resistance 565
 - hypertrophy, diabetes – insulin, effect of 135
 - octreotide, effect of 135
 - osteonectin (SPARC) and A62
 - tubular function – NIDDM A218
- Renin – plasma activity – diabetes 1443
- Renin-angiotensin system – glycaemic control and – IDDM A214
- Respiratory function – Type 1 diabetes A187
- Retina – advanced glycation end-products, toxicity of A161, A162
- basement membrane – streptozotocin-diabetic rat 269
 - endothelial cell – replication A145
 - glucose phosphorylation A145
 - hypotensive drugs, effects of A58
 - photography – 45-degree 437
 - photostress 804
- Retinopathy – diabetic A275–A279
- albumin excretion rate and – EURO-DIAB Study 599
 - aminoguanidine, effect of – diabetic rat 656
 - early changes – aminoguanidine, unaffected by 269
 - grading – retinal photography 437
 - growth factors A57
 - incidence A57

Rhesus monkey

- islet transplantation, effect of -- diabetic rat 656
- progression -- UK prospective diabetes study A 58
- screening -- retinal photography 437
- streptozotocin-diabetic rat 269, 656
- Rhesus monkey [see *Macaca mulatta*]
- Rheumatoid arthritis -- islet-cell antibodies in 351
- Risk -- diabetes -- Type 1 -- recurrence in children 975
- Type 2 -- parental diabetic nephropathy 1486c
- -- parental diabetic nephropathy 221
- macrovascular disease [see Cardiovascular -- risk factor]

S

- Scintigraphy -- ¹²³I-MIBG 1345
- ^{99m}Tc-methoxyisobutylisonitrile 1345
- thallium -- screening for coronary heart disease 726
- Screening -- diabetic neuropathy A 235, A 236
- diabetic retinopathy -- primary care A 278
- -- retinal photography 437
- Selectin [see Adhesion molecule/]
- Selenium compounds -- glucose transport, stimulation of A 133
- Sex hormone binding globulin -- gestational diabetes and A 284
- Shock -- hypovolaemic -- alkali infusion in 889
- Sialic acid, serum -- diabetic nephropathy A 217
- lipid-associated A 270
- Skin -- blood flow -- diabetes 467
- Sleep -- glucose homeostasis and A 148
- Smoking -- hypertriglyceridaemia, role in 1358
- mortality in haemodialysis for diabetic nephropathy, effect on A 209
- serum insulin, effect on -- two-site immunometric assay A 223
- Sodium transport -- Na⁺/H⁺ -- diabetic cardiomyopathy and A 266
- -- endothelial cell -- glucose, effect of 785
- -- families of Type 1 diabetes A 230
- Na⁺/K⁺ ATPase -- inhibitor -- insulin resistance, effect in 792
- -- myo-inositol feeding, effect of 899
- -- renal tubule A 64
- Na⁺/Li⁺ counterport -- albumin excretion rate and 356
- -- cardiovascular risk factor and -- NIDDM A 229
- -- insulin resistance and A 224
- -- left ventricular mass and 454
- Somatostatin -- insulin secretion, effect on A 124
- pancreatic acinar cells, binding to 262
- receptor -- Type 5 -- islet B-cell A 106
- Sorbitol -- dehydrogenase -- inhibitor -- diabetic neuropathy, effect on A 232
- SPARC (secreted protein acidic and rich in cysteine) [see Osteonectin/]
- SPECT (single-photon emission CT) [see Brain -- perfusion/]
- Spodoptera frugiperda* -- cell -- transfection -- human GAD65 14

- Sports [see Exercise/]
- Statin [see HMG CoA reductase inhibitor/ A 258]
- Stereology -- glomerular [see Glomerular -- morphometry; Heart -- cardiomyopathy/]
- Steroid [see Glucocorticoid/]
- Streptozotocin -- diabetes -- low-dose -- GLUT2 role A 134
- Stress -- life events -- glucose tolerance and A 61
- protein [see Heat shock protein/]
- sympatho-adrenal response -- hyperglycaemia, effect of A 147
- Stroke A 270
- diabetes 1061
- diabetic autonomic neuropathy, increased risk in A 240
- epidemiology -- Sweden 1061
- Sulphatide -- islet, synthesis in A 45
- Sulphonylurea A 196, A 197
- cardiovascular effects 116r
- glibenclamide 1025
- glyburide -- placental handling -- rat 753
- insulin secretion, effect on A 107
- K⁺ ATP channel, effect on 1025, A 43
- proinsulin levels, effect on A 115
- receptor -- gene -- Type 2 diabetes linkage studies negative 1479
- -- insulin-secreting cell 277
- -- troglitazone, effect of 24
- therapy -- glycogen synthase expression, no effect on 1230
- -- lipolysis, effects on A 247
- -- UK Prospective Diabetes Study A 24
- Suramin -- neuropathy A 234
- Synaptic vesicle docking -- syntaxin -- islet B-cell, present in 860
- Syndrome X -- metabolic [see Insulin -- resistance -- syndrome/]
- Syntaxin 1 -- islet B-cell, role in A 123

T

- Tamm-Horsfall protein [see Protein -- Tamm-Horsfall/]
- Taste sensation -- diabetes A 186
- Taurine -- insulin secretion, effect on A 104
- Temperature -- insulin secretion, effect on A 124
- Thapsigargin -- insulin secretion, effect on A 109
- Thiazide -- low-dose 853
- Thiazolidinediones [see Hypoglycaemic agent -- thiazolidinediones/]
- Thioctic acid (lipoic acid) -- cataract protection A 277
- diabetic neuropathy, effect on -- streptozotocin diabetes A 231
- glucose oxidation, effect on -- obese NIDDM A 41
- glucose transport, effect on A 132, A 133
- skeletal muscle, effect on -- Zucker rat A 142
- therapy -- diabetes, Type 2 A 199
- -- diabetic neuropathy 1425
- Thyroid [see also Hyperthyroidism/]
- autoimmune disease in Type 1 diabetic families A 90
- function -- elderly NIDDM, in A 185
- glucose transport, effect on -- rat adipocyte A 135

- TNFA [see Tumour necrosis factor α/]
- Tocopherol [see Vitamin E/]
- Transfection -- human proinsulin gene -- retroviral vector A 84
- insulin receptor gene -- Chinese hamster ovary cells 180
- Transplantation -- bone marrow -- hyperinsulinaemia A 14
- heart -- glucose tolerance -- islet amyloid and A 14
- insulin-secreting cell -- transgenic A 55
- islet [see also EASD -- Study Group -- AIDSPIT/ A 83]
- -- adrenergic responsiveness A 85
- -- amino-acid metabolism following A 23
- -- body composition, effect on 881
- -- diabetic nephropathy prevention A 208
- -- diabetic retinopathy, effect on -- diabetic rat 656
- -- energy metabolism, effect on in diabetic rat 919
- -- function A 55
- -- glucotoxicity A 85
- -- immunoalteration A 56
- -- immunoisolation A 84
- -- interleukin-10 transfection A 56
- -- intraportal A 56
- -- -- long-term evaluation in rat 1007
- -- microencapsulation A 56
- -- nicotinamide protection A 56
- -- xenograft -- human to nude mouse 543
- kidney -- diabetes following A 14
- liver -- lipotrophic diabetes A 140
- -- non-esterified fatty acid metabolism A 14
- pancreas A 83
- -- hypoglycaemia following A 19
- Transporter -- antigen processing -- gene in Type 1 diabetes A 72
- Triglyceride -- subcutaneous monitoring for hypoglycaemia A 202
- Trigonella foenum graecum* (Fenugreek) A 101
- Triphenyltin -- insulin secretion, inhibition of A 118
- Troglitazone [see Hypoglycaemic agent -- thiazolidinediones/]
- Tumour necrosis factor α -- adipocyte, effect on 764
- cachexia, role in? 764
- insulin receptor, effect on A 136
- Type 2 diabetes -- coronary disease A 19
- Tungsten [see Hypoglycaemic agent -- vanadate/ A 143]
- Tyrosine kinase [see also Insulin -- receptor/]
- C -- islet B-cell -- neurotrophin-3 receptor A 106
- focal adhesion kinase -- phosphorylation 1131
- islet B-cell cytoplasmic -- Bsk A 94
- phosphoinositol metabolism, role in -- islets A 117

U

- Ulcer -- foot [see Foot/]
- Ultrasonography -- B mode 585
- Doppler 555
- echo tracking -- arterial compliance 1082
- Urinary bladder [see Bladder/]

- Urine – albumin excretion rate [*see* Albumin – excretion rate/]
- IgA – diabetic nephropathy progression and A 210

V

- Vanadate [*see* Hypoglycaemic agent – vanadate/]
- Vascular – compliance A 268
- disease [*see also* Heart/; Macrovascular disease; Microangiopathy/]
- – peripheral – treatment – diabetic neuropathy, effect on 1051
- – Type 2 diabetes – UK Prospective Diabetes Study A 19
- proliferation – diabetes A 254, A 255
- reactivity – coronary 1157
- – diabetes A 261–A 265
- – – aldose reductase inhibitor, effect of A 255
- – – Type 2 1337
- – diabetic neuropathy, in A 230
- – insulin, effect of – cAMP and cGMP involved 936
- – – normal human 467
- Vasoactive intestinal polypeptide [*see* VIP/]
- Vasodilatation – insulin-induced A 157
- VIP (Vasoactive intestinal polypeptide)
- diabetic autonomic neuropathy A 239
- insulin secretion, effect on A 101
- Virus – baculo- – transfection, use in 14
- Coxsackie B – pregnancy – Type 1 diabetes risk in child 1371
- cytomegalo – Type 1 diabetes 667, 705
- EMC – diabetes induction in mice – insulin prophylaxis A 97
- entero – islet B-cell injury A 16
- Epstein-Barr – islet-cell antibody seroconversion and 1130c
- – Type 1 diabetes 667
- pancreas – Type 1 diabetes – pancreas biopsy at diagnosis 667
- – Type 2 diabetes A 79
- Vision – evoked potentials – diabetes 573
- flash electroretinography – early IDDM 804
- macular function – early IDDM 804

Wortmannin

- Vitamin – C [*see* Antioxidant/]
- D – deficiency – glucose homeostasis in 1239, A 113
- E [*see also* Antioxidant/]
- – coronary vascular reactivity, effect on – diabetic rat 1157
- – diabetic embryopathy, effect on A 22
- – diabetic nerve, effect on 129
- – insulin resistance syndrome, effects in A 166
- – oxidative stress, effect on – insulin resistant rat A 41
- – Type 1 diabetes – disease-modifying therapy A 99
- – vascular reactivity, effect on – diabetic rat 1475

W

- War – incidence of Type 1 diabetes 550
- WHO (World Health Organisation) – MONICA Project 1061
- Wortmannin [*see* Phosphatidyl-inositol 3'-kinase – inhibitor/]



